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Human malaria is responsible for over 700,000 deaths a year. To stay abreast of the 
threat posed by the parasite, a constant stream of new drugs and vector control methods 
are required. This study focuses on a vaccine that has the potential to protect against 
parasite infection, but has been hindered by developmental challenges. In malaria 
prevention, live, attenuated, aseptic, Plasmodium falciparum sporozoites (PfSPZ) can 
be administered as a highly protective vaccine. PfSPZ are produced using adult female 
Anopheles stephensi mosquitoes as bioreactors. Production volume and cost of a PfSPZ 
  
vaccine for malaria are expected to be directly correlated with Plasmodium falciparum 
infection intensity in the salivary glands. The sporogonic development of Plasmodium 
falciparum in A. stephensi to fully infected salivary gland stage sporozoites is dictated 
by the activities of several known components of the mosquito’s innate immune 
system. Here I report on the use of genetic technologies that have been rarely, if ever, 
used in Anopheles stephensi Sda500 to increase the yield of sporozoites per mosquito 
and enhance vaccine production. By combining the Gal4/UAS bipartite system with in 
vivo expression of shRNA gene silencing, activity of the IMD signaling pathway 
downstream effector LRIM1, an antagonist to Plasmodium development, was reduced 
in the midgut, fat body, and salivary glands of A. stephensi. In infection studies using 
P. berghei and P. falciparum these transgenic mosquitoes consistently produced 
significantly more salivary gland stage sporozoites than wildtype controls, with 
increases in P. falciparum ranging from 2.5 to 10 fold. Using Plasmodium infection 
assays and qRT-PCR, two novel findings were identified. First, it was shown that 14 
days post Plasmodium infection, transcript abundance of the IMD immune effector 
genes LRIM1, TEP1 and APL1c are elevated, in the salivary glands of A. stephensi, 
suggesting the salivary glands may play a role in post midgut defense against the 
parasite. Second, a non-pathogenic IMD signaling pathway response was observed 
which could suggest an alternative pathway for IMD activation. The information 
gained from these studies has significantly increased our knowledge of Plasmodium 
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Chapter 1: Introduction & Literature Review 
 
 Statement of Purpose 
Human malaria is responsible for over 700,000 deaths a year (WHO 2014). To 
stay abreast of the threat posed by the parasite, a constant stream of new drugs and 
vector control methods are required (WHO 2014). Vector control is one of the most 
effective strategies used for the suppression of mosquito-borne diseases (Rani et al. 
2009). In areas where malaria is endemic, insecticide spraying and insecticide-treated 
bed nets have proven effective in reducing transmission (Christophides 2005). 
Advancements in mosquito molecular genetics have enabled researchers to target the 
mosquito immune system to deplete or incapacitate the disease transmitting population 
(Christophides 2005). Presently, one of the most promising methods of disease control, 
proposes the use of vaccines developed from live radiation attenuated sporozoites 
(RAS) (Hill 2011). In clinical studies, a live RAS vaccine developed by Sanaria Inc, a 
biotechnology company in Rockville Maryland conferred protection against the 
development of blood stage infection to 100 percent of the volunteers (Seder et al. 
2013). However, vaccine production is limited in part by the number, also referred to 
as intensity, of sporozoites in the mosquito salivary glands. The effective immune 
system of the mosquito in particular the immune deficiency pathway (IMD), is able to 
kill the parasite, reducing the number of sporozoites reaching the salivary glands. We 
hypothesize that mosquitoes with modified innate immune systems can enhance the 
susceptibility to Plasmodium falciparum thereby increasing sporozoite intensity and 




a key role in anti-Plasmodium resistance in mosquitoes (Fraiture et al. 2009). Recent 
studies have shown that leucine-rich repeat immune molecule 1 (LRIM1),  an effector 
gene in the IMD pathway, functions in a complement-like mechanism leading to the 
targeting and destruction of Plasmodium parasites (Fraiture et al. 2009; Baxter et al. 
2010; Povelones et al. 2011; Garver et al. 2012). In this study we will examine the 
current models of LRIM1 anti-Plasmodium response and expression in Anopheles 
stephensi (A. stephensi), by employing techniques novel to the field of vector biology. 
We hope our findings will give us a better understanding of the biology of LRIM1 in 
A. stephensi and ultimately lead to our ability to increase sporozoite infection intensity 













 The Global Impact of Human Malaria   
Human malaria, is a persistent global public health threat and the leading cause 
of death in many developing countries (WHO 2014). More than 3 billion individuals 
live in 106 malaria endemic countries (Figure 1.1), with 1.2 billion in areas where the 
chance of getting human malaria is greater than 1:1000 (WHO, 2014).  In 2013 there 
were an estimated 283 million clinical cases and 755,000 deaths attributed to human 
malaria worldwide. Ninety percent of those deaths occurred in the African region, with 
an estimated 76% being children under the age of five (WHO 2014).  The severity of 
the disease in the African region is a result of several factors. 1) A very efficient vector, 
Anopheles gambiae; 2) The parasite species predominantly found in the region, 
Plasmodium falciparum, is most likely to cause severe illness and death; 3) The climate 
is conducive to year round transmission and 4) economic instability in the region 
(WHO 2014). 
Human malaria has a substantial economic impact, costing more than US$ 12 
billion per year with even more significant indirect costs. Infected individuals incur 
treatment related costs in addition to reduced income resulting from lost work days 
(WHO). Globally, human malaria infection is the 8th leading cause of Disability 
Adjusted Life Years (DALYs) and is the 2nd leading cause of DALYs in Africa (Snow 
et al., 2003). Governments also incur significant costs to purchase drugs, maintain 
health facilities and carry out public health interventions such as insecticide spraying 




The United Nations World Tourism Organization (UNWTO) estimates that by 
2020, 800 million travelers will visit a country at risk for human malaria transmission 
every year. Infected travelers or migrants who travel to countries that have eradicated 
malaria or have very low transmission can expose a very susceptible population to the 
disease. Even though malaria has been eliminated in the United States and some parts 
of Europe, there is still the possibility of outbreaks (WHO 2014). Since 1950, there 
have been 63 outbreaks in the U.S.A, (CDC) and malaria vectors, A. quadrimaculatus, 
A. freeborni, and A. albimanus are still widely prevalent in North America, making 













Figure 1.1- Global cases of human malaria in 2013. Human malaria is one of the 
world’s most severe public health problems. An estimated 3.3 billion individuals live 
in 106 human malaria endemic areas. 1.2 billion individuals live in areas where the 
chance of getting human malaria is greater than 1:1000. Ninety percent of all malaria 











 Malaria Parasitology & Prevention 
 
The malaria parasite is a single cell protozoan of the genus Plasmodium with a 
complex life cycle that involves the Anopheles vector and a vertebrate host. There are 
five Plasmodium species that infect humans (P. falciparum, P. vivax, P. ovale, P. 
malariae and P. knowlesi) (White 2008) and all five exhibit a similar life cycle (Wiser 
2009) 
An individual develops malaria after being bitten by a female Anopheles 
mosquito infected with the Plasmodium parasite.  When the female mosquito bites an 
individual, sporozoites in the mosquito saliva are injected into the human host during 
feeding (Hill 2011) (Figure 1.2). Sporozoites enter the blood stream from the avascular 
tissue and are carried by the circulatory system to the liver and invade hepatocytes 
(Vanderberg and Frevert 2004; Vaughan et al. 2008).  The intracellular sporozoites 
undergo asexual reproduction known as exoerythrocytic schizogony that culminates in 
the production of merozoites that are later released from ruptured hepatocytes into the 
blood stream (Vaughan et al. 2008). Circulating merozoites invade erythrocytes and 
enter a trophic period where the parasite enlarges forming a ring structure (Bannister 
et al. 2000). The trophozoite enlargement is accompanied by active metabolism within 
the blood cell that involves ingestion of the host cytoplasm and proteolysis of 
hemoglobin into amino acids (Soulard et al. 2015). At the end of the trophic period 
there are rounds of nuclear division, without cytokinesis that results in a schizont. 
Merozoites bud from these mature schizonts and are released after rupture of the 
erythrocyte (Huff and Coulston 1944; Soulard et al. 2015). The invasion of the 




stage replicative cycle (Rosenmund 1991; Cox 1991). Blood stage infection is 
responsible for the pathology associated with human malaria. (Suhrbier 1991; 
Rosenmund 1991; Cox 1991). Malaria patients suffer from intermittent fever paroxysm 
caused by the synchronous rupture of infected erythrocytes. Symptoms can last 48 to 
72 hours depending on the Plasmodium species. In the case of Plasmodium falciparum 
fevers are persistent and result in higher morbidity and mortality (Rosenmund 1991). 
The increased virulence of P. falciparum is also due in part to the higher level of 
paracetemia. Also the sequestration of trophozoites and schizont-infected erythrocytes 
in deep tissue results in more complications (Suhrbier 1991; Cox 1991; Rosenmund 
1991) 
The parasite can develop into two sexual forms called microgametocytes and 
macrogametocytes. Gametocytes are large parasites that contain only one nucleus and 
fill up the erythrocytes (Ott 1967; Soulard et al. 2015). During a blood meal from a 
vertebrate host, the female Anopheles ingests gametocyte infected erythrocytes. The 
drop in temperature from the host to the mosquito, an increase in carbon dioxide and 
other mosquito metabolites induces gametogenesis and escape of microgametes and 
macrogametes from the erythrocytes (Soulard et al. 2015). Marcogametes are fertilized 
by microgametes to form a zygote. The zygote develops into a mobile okinete which is 
able to traverse the midgut epithelium and form a robust oocyst that undergoes multiple 
rounds of replication to produce sporozoites (Shahabuddin 1998). Rupture of the 
oocysts releases the sporozoites into the hemocoel of the mosquito. The sporozoites 




Historically, human malaria control has involved a combination of vector-based 
interventions and antimalarial drugs (WHO 2008). Traditional interventions included 
the use of insecticides, physical barriers such as bed nets and destruction of mosquito 
breeding sites (Walker 2002). Past eradication initiatives have been successful in parts 
of Europe and North America due in principle to control of the mosquito vector 
populations and access to effective medical treatment (Walker 2002). However new 
human malaria cases continue to arise in part due to insecticide-resistant vectors and 
drug-resistant parasites among other challenges (WHO 2008). These failures have 
stipulated the need for integrative malaria interventions that utilize innovative scientific 
research to interrupt transmission at all stages of the parasite life cycle (WHO 2008). 
Vaccines have the potential to interrupt the human malaria parasite at different stages 
in the life cycle, however low efficacy and coverage in vaccine trials, coupled with 









Figure 1.2- Life cycle of the malaria parasite. Diagram depicts the mosquito vector 
stage of the life cycle on the left and the vertebrate host stage on the right. Generally, 
the life cycle for all Plasmodium species is the same. (Adapted from “Creative 
Commons Falciparum life cycle” by Le Roche Lab UC Riverside, used under CC BY 




 Developing Vaccines against Malaria 
The challenge of developing a highly effective malaria vaccine has led to the 
design and assessment of a wide range of new approaches (Hill 2011). Early infection 
studies using radiated sporozoites in mice (Nussenzweig et al. 1967) and later in 
humans (Clyde et al. 1975), coupled with the analysis of the mechanism of immunity 
(Doolan and Hoffman 1997) have formed the basis for modern malaria vaccine 
development. The aforementioned studies by Clyde and colleagues demonstrated that 
a high level of protection to subsequent malaria infections could be induced in humans 
after being bitten by irradiated infectious mosquitoes.  
Pre-erythrocytic Vaccines 
Vaccines that aim to protect against development of the parasite in the 
hepatocytes are termed pre-erythrocytic vaccines (Chia et al. 2014). These vaccines 
stimulate an immune response to prevent infection of hepatocytes or attack already 
infected cells (Hill 2011). The Malaria Vaccine Institute categorizes these vaccines as 
such: 
 Live, attenuated vaccines that contain of a weakened form of the whole parasite (the 
sporozoite) as the vaccine's main component. 
 Vectored/Recombinant or genetically engineered antigens from the surface of the 
parasite or from the infected liver cell. 






Whole Parasite Vaccines 
The development of a whole parasite vaccine for human malaria had been 
considered clinically impractical (Hoffman et al. 2010). Studies with humans Clyde, 
Mccarthy, et al. (1973); Clyde, Most, et al. (1973) and Clyde et al. (1975; Hoffman et 
al. 2002) demonstrated that for high-level efficacy, individuals required approximately 
1000 bites from infected mosquitoes, an impractical method for public administration 
of a vaccine. High efficacy also required the parasites be alive when administered, 
meaning the vaccine would have to be injectable. In addition, the vaccine would need 
to be stable, cryopreservable, aseptic and scalable for large quantity manufacturing.  
(Hoffman et al. 2010; Hill 2011). Despite the challenges facing this approach, a major 
effort has been made by a US biotech company, Sanaria, to develop a pre-erythrocytic 
vaccine comprising whole sporozoites (Hoffman et al. 2010). The catalyst behind this 
approach is the knowledge that irradiated sporozoites delivered by mosquito bites have 
induced very high levels of protective efficacy. In 2013, Sanaria reported the results of 
clinical trials which showed that a live radiation attenuated Plasmodium falciparum 
sporozoites vaccine (RA PfSPZ) conferred protection against the development of blood 
stage infections. Twelve of fifteen volunteers immunized using the live RA PfSPZ 
vaccine were protected against blood stage malaria including 100% protection for 6 
volunteers who received higher doses (Seder et al. 2013). Live attenuated irradiated 
sporozoites are able to invade liver cells but develop into defective schizonts that 
cannot rupture the hepatocytes to release merozoites that would normally invade red 
blood cells resulting in blood stage malaria. These defective schizonts express antigens 




whole parasite approach was likely achieved through the activity of induced CD8 T 
cells that clear infected human liver cells, but this remains to be demonstrated (Hill 
2011). Even though high-level efficacy can be achieved using this approach, the 
challenge of manufacturing cost remains (Chia et al. 2014).  
Efforts have also been made to eliminate the need for irradiating sporozoites. 
Genetically attenuated sporozoites that are incapable of developing beyond the liver-
stage of the disease are being developed (Vaughan et al. 2010). Parasites engineered to 
progress to a later stage of development within the hepatocytes than irradiated parasites 
could present more antigens and possibly be more efficacious (Vaughan et al. 2010). 
With no radiation however, there are concerns about the safety and the possibility of 
break-through infections even if multiple mutations are introduced (Hill 2011).  
In an extension to the whole parasite vaccines approach, researchers have 
investigated the possibility of using blood stage whole parasites to induce immunity 
(Hill 2011; Butler et al. 2012). In clinical trials it was demonstrated that very low, 
repeated doses of blood stage whole parasite could induce immunity to subsequent 
challenges in both animals and humans in the absence of induced antibodies. 
(McCarthy and Good 2010). However a major challenge to this approach is an 
acceptable method for growth of large enough numbers of parasites in blood or blood 
substitute (McCarthy and Good 2010).  
Vectored/Recombinant Vaccines  
These pre-erythrocytic vaccines are aimed mainly at inducing cellular 




mimic the mechanism of the immune response to irradiated sporozoites observed in 
animal models which is due to chiefly to CD8 T cells and appears to target multiple 
antigens (Doolan and Hoffman 1997). Several generations of vectored vaccines have 
been assessed clinically in attempts to induce comparable efficacy (Hill 2011). 
However, generating  high-level efficacy with vectors encoding single antigens has 
proven to be difficult, in part because the levels of T cells required are exceptionally 
high (Reyes-sandoval et al. 2010) and also because of the large number of protein 
antigens (>5,000) expressed by the eukaryotic parasite and the complexity of the 
organism (Gardner et al. 2002; Butler et al. 2012). Eukaryotic parasites have complex 
multi-stage life cycles and at each stage there can be an enormous variation in the 
proteins expressed ( >5,000) (Gardner et al. 2002; Butler et al. 2012). To increase T 
cell levels a “prime boost” approach (Ewer et al. 2013) has been developed that uses 
chimpanzee adenoviruses (ChAds) encoding  a pre-erythrocytic antigen, 
thrombospondin-related adhesion protein (TRAP) and another viral vector, modified 
vaccinia virus Ankara (MVA) that encodes another copy of TRAP to prime an immune 
response (Hill et al. 2010; Reyes-sandoval et al. 2010). Other priming methods using a 
DNA priming vector and a human adenovirus Ad5 have also been developed (Chuang 
et al. 2013). To date further antigens including circumsporozoite protein (CSP) and the 
blood-stage antigens apical membrane antigen-1 (AMA1) and merozoite surface 
protein-1 (MSP1) have been assessed (Chia et al. 2014; Foquet et al. 2014). 
Blood-stage Vaccines  
Blood-stage vaccines target the most destructive stage of the parasite life cycle; 




erythrocytic vaccines, blood stage vaccines do not aim to block all infections but 
decrease the number of parasites in the blood, and in so doing, reduce the severity of 
disease (Goodman and Draper 2010). Evidence suggests that people who have survived 
regular exposure to malaria develop natural immunity over time. The goal of a vaccine 
that contains antigens or proteins from the surface of the blood-stage parasite (the 
merozoite) would be to allow the body to develop that natural immunity with  less risk 
of getting ill (Osier et al. 2014). 
Development of blood-stage vaccines has generally been slower compared to 
pre-erythrocytic vaccines (Goodman and Draper 2010). Blood stage vaccines that have 
progressed to clinical studies have not yet achieved good evidence of protective 
efficacy against clinical malaria. Many of these vaccine candidates are based on just a 
few antigens, MSP1 and AMA1 in particular, although there are hundreds or perhaps 
thousands of antigens expressed by blood-stage parasites that might be used in vaccine 
development (Chia et al. 2014; Osier et al. 2014). Majority of these candidate vaccines 
have been a protein-adjuvant combination designed to induce protective antibodies that 
impair parasite growth (Ellis et al. 2009; Druilhe et al. 2005). Three particular 
challenges for the development of blood-stage vaccines are 1) Large-scale production 
of conformationally correct large antigens, 2) weak antibody response (Ellis et al. 2009) 
and 3) the extensive polymorphism of many leading candidate blood-stage antigens 







Transmission-Blocking Vaccine (VIMTs) 
Transmission-blocking vaccines work by inducing antibodies that interrupt 
development of the parasite in the mosquito after it takes a blood meal from a 
vaccinated person (Coutinho-Abreu and Ramalho-Ortigao 2010; Arévalo-Herrera et al. 
2011; Nunes et al. 2014). Transmission-blocking vaccines would not prevent a person 
from getting malaria, nor lessen the symptoms of the disease but would limit the spread 
of infection by preventing mosquitoes that fed on an infected person from spreading 
malaria to new hosts (Hill 2011). Antigens from the gametocyte or sexual stage of the 
malaria parasite are used to immunize individuals (Rhoel R. Dinglasan and Marcelo 
Jacobs-Lorena 2008). The principle that immunization with gametocyte or ookinete 
antigens could reduce or ablate oocyst development in the mosquito was first reported 
by (Carter & Chen 1976).  However, concern that utilization of such a transmission-
blocking vaccine would be impractical because of the mass vaccination needed initially 
limited development. However, new findings such as the possible ookinete receptor, 
aminopeptidase (APN1), along with the potential cross species activity of transmission 
blocking vaccines, has rekindled interest (Dinglasan et al. 2007).  
Sanaria’s Malaria Vaccine: RA-PfSPZ  
Sanaria is a biotechnology company located in Rockville Maryland with a 
mission to develop and commercialize a whole-sporozoite vaccine that confers high-
level, long-lasting protection against the malaria parasite Plasmodium falciparum. 
(Sanaria Inc.).  Results of a small human experiment reported in 2013 demonstrated 
100% protection against blood stage infection for volunteers who received a high dose 




the potential to be the largest revenue producing vaccine in the world, generating $1- 
$3 billion annually with many potential markets that include military personnel, 
government officials, and tourists who travel to malaria endemic countries.  
Manufacturing  of the RAPfSPZ vaccine is an expensive and labor intensive 
process that involves manual dissection of the salivary glands of infected female A. 
stephensi Sda 500 mosquitoes followed by purification of sporozoites away from the 
mosquito tissue and cells (Hoffman et al. 2010). Sanaria calculates that the cost of their 
RAPfSPZ vaccine is directly related to the number of sporozoites that develop in each 
infected salivary gland. Therefore, any increase in manufacturing efficiency will have 
a direct impact on reducing the cost of production. To improve manufacturing 
efficiency Sanaria plans to adapt genetically modified A. stephensi Sda500 that regular 
yield more sporozoites than the wildtype mosquito to their manufacturing platform. 
 The Anopheles Mosquito: The Malaria Vector 
 
The Anopheles genus of mosquitoes is comprised of almost 500 species of 
which only 8-10% are vectors of the human malaria parasite (Collins and Paskewitz 
1995). A. gambiae, the primary vector in the African region is the most studied species. 
Other species, such as A. stephensi, and A. darlingi are important vectors in Southeast 
Asia and South America, respectively (Sinka et al. 2012). See Figure 1.3 for a map of 
global malaria vectors. Various Anopheles sub-species and reproductively isolated 
genetic forms also contribute to the complexity of the genus (Lee et al. 2013; Lefèvre 
et al. 2009). For instance, A. gambiae is a species complex comprised of many 




hypothesized that genetic adaptations to varying environments among other factors 
drive speciation within the Anopheles genus (Caputo et al. 2014). Anopheles stephensi 
Sda500 used in the vaccine manufacturing platform of Sanaria , is a laboratory strain 
that was obtained through genetic selection of female mosquitos of the Sind strain that 
were exposed to highly infective in-vitro reared P. falciparum gametocytes (Feldmann 
and Ponnudurai, 1989).  Feldman and Ponnudurai observed that Sda500 yielded twice 
as many oocyst in the midgut than the unselected Sind strain.  
Regardless of environmental adaptive differences, Anopheles mosquitoes 
undergo a similar life cycle. Anautogenous adult females require a blood meal to 
produce eggs. Gravid females will oviposit approximately 50-200 eggs approximately 
48-72hrs post blood-meal in a suitable, aqueous environment. Under optimal 
conditions most of the eggs will hatch within 3 days of oviposition, however 
temperature variability can result in hatch times 2-30 days or longer. Larvae cycle 
through 4 developmental stages (L1, L2, L3, L4) that can range from 5-14 days (Bray 
& Garnham 1982) . After the L4 stage, larvae pupate and undergo metamorphosis into 
adults (Charlesworth 2014). After mating males typically die off whereas females go 
in search of a blood meal. Anopheles mosquitoes are anautogenous and the female 
mosquito requires a blood meal to produce eggs to continue the life cycle (Hillyer 
2010). Females may take more than one blood meal during their life span, and these 








Figure 1.3- Geographic location of malaria vectors. Distribution of mosquitoes of the 




 Unravelling the Mosquito Immune System for Malaria Control 
The Anopheles genome contains many uncharacterized genes that are regulated 
by Plasmodium infection (Dong et al. 2006). Genome re-sequencing, high throughput 
transcriptomics analysis of malaria vectors, coupled with the advances in mosquito 
molecular genetics, have enabled researchers to identify genes potentially involved in 
insecticide resistance, host and mate seeking behaviors and refractoriness to 
Plasmodium (Lynd and Lycett 2012). Recent proposals aimed at preventing parasite 
transmission include creating Plasmodium resistant mosquitoes and introduction of 
transgenic mosquitoes into native mosquito habitats that will convert later generations 
of mosquitoes into non-vectors (Marshall and Taylor 2009).  
Anopheles gene function has been primarily characterized through the use of 
transient RNA interference (RNAi) (Shin, V.A. Kokoza, et al. 2003). Although 
functional characterization of genes using transient RNAi is possible in adult 
mosquitoes (Catteruccia and Levashina 2009) this method is limited not least by the 
non-systemic nature of gene silencing in mosquitoes (Lycett et al. 2006). The 
Gal4/UAS bi-partite system (Figure 1.4) is a powerful functional genomics tool that 
has been routinely used with great success in Drosophila and has been more recently 
adapted for use in Anopheles (Lynd & Lycett 2012; O’Brochta et al. 2012). The system 
can be used in a wide variety of applications such as generating phenotypes through 
transgene mis- or over-expression, enhancer detection and stable gene knockdown 




The bi-partite system uses a transgenic “driver” line with the yeast 
transactivator, Gal4, under the transcriptional control of a specific regulatory region; 
and a transgenic ‘‘responder’’ line that contains a candidate gene under the 
transcriptional control of an upstream activation sequences (UAS) containing multiple 
Gal4 binding sites (Fischer et al. 1988; Ornitz et al. 1991; Brand and Perrimon 1993). 
Since most species, do not contain Gal4 equivalents, the candidate gene is only 
expressed in the progeny of crosses between driver and responder lines, when Gal4 and 
UAS transgenes are brought together in the same genome (Lynd and Lycett 2012). The 
expression of the candidate gene is dictated by the temporal and spatial pattern of the 
promoter or enhancer driving Gal4 expression (Lynd and Lycett 2012). Analysis of 
genes whose expression may exert a high fitness cost or dominant lethal or sterile 
phenotypes is also possible, since activation only occurs after crossing. Thus the effects 
of mis-expression can be studied even if they are somewhat deleterious (Brand and 









Figure 1.4- Gal4/UAS bi-partite system. The Gal4/UAS system utilizes a transgenic 
“driver” line with the yeast transactivator, Gal4, under the transcriptional control of a 
specific regulatory region; and a transgenic ‘‘responder’’ line that contains a candidate 
gene under the transcriptional control of the upstream activation sequences (UAS) also 
known as Gal4 binding sites. The system can be used to control the spatial and temporal 
pattern of a candidate gene expression and to analyze gene that may have a high fitness 




 Mosquito Innate Immunity 
Mosquitoes like other organisms are exposed to the constant threat of infection 
and are specifically susceptible to infection by blood-borne pathogens such as 
Plasmodium during a blood meal (Hillyer 2010). Invertebrates including mosquitoes 
lack an adaptive immune system but utilize a highly effective innate immune system 
for their defense (Osta, Christophides, Vlachou, et al. 2004), (Dimopoulos 1997) 
During Plasmodium infection the innate immune system in combination with physical 
barriers such as the peritrophic matrix (PM) can reduce parasitemia 107 fold (Alavi et 
al. 2003; Hillyer 2010). Three major immune signaling pathways that have been 
demonstrated to protect the mosquito from pathogens are; the Toll pathway, the 
Jak/Stat pathway and the IMD pathway (figure1. 5) (Dimopoulos 1997; Christophides, 
Zdobnov, Barillas-Mury, Birney, Blandin, Blass, Brey, Collins, Danielli, Dimopoulos, 
Hetru, Hoa, J. a Hoffmann, et al. 2002; Shin, V. Kokoza, et al. 2003; Osta, 
Christophides, Vlachou, et al. 2004; Cirimotich et al. 2010; Yassine and M. a Osta 
2010; Hillyer 2010; Pike et al. 2014) 
Toll Pathway 
The Toll pathway is activated during invasion by gram positive bacteria or fungi 
(Cirimotich et al. 2010). It has also been implicated in defense against viruses in 
mosquitoes (Xi et al. 2008) and fruit flies (Zambon et al. 2005). In the Anopheles 
malaria vector the Toll pathway has been demonstrated to respond to rodent malaria, 
Plasmodium berghei infection (Frolet et al. 2006). Pathogen associated molecular 
patterns (PAMP) are recognized by pathogen recognition receptors (PRR) such as 




to and activates the Toll receptor. This triggers signaling through the adaptor proteins 
MyD88, Tube, and Pelle, resulting in the phosphorylation and degradation of the Toll 
pathway negative regulator Cactus (Ip et al. 1993; Barillas-Mury et al. 1996; Han and 
Ip 1999; Manfruelli et al. 1999; Meng et al. 1999; Christophides, Zdobnov, Barillas-
Mury, Birney, Blandin, Blass, Brey, Collins, Danielli, Dimopoulos, Hetru, Hoa, J.A. 
Hoffmann, et al. 2002). Degradation by Cactus enables the NF-kappa-B like Rel1 
transcription factor to translocate to the nucleus and initiate transcription of Toll 
pathway immune factors (Belvin et al. 1995; Barillas-Mury et al. 1996; Wu and 
Anderson 1998).  
JAK-STAT Pathway 
The JAK-STAT pathway named for the Jak kinase and STAT transcription 
factor has been demonstrated to play a role in the immune response against pathogenic 
bacterial infections in the gut of Drosophila (Buchon et al. 2009; Cronin et al. 2009) 
and against viral activity in  Drosophila (Dostert et al. 2005) and Aedes aegypti (Souza-
Neto et al. 2009). Gupta et al. 2009 demonstrated that the JAK-STAT pathway plays a 
role in P. falciparum and P. berghei infections post midgut stage infection however the 
mechanism by which this is done is less understood (Cirimotich et al. 2010). Activation 
of the JAK-STAT pathway is triggered by Unpaired (Upd) binding to the receptor 
Dome, activating the receptor-associated Hop Janus kinases, which phosphorylate each 
other and recruit and phosphorylate STAT. STAT undergoes dimerization and 
translocates to the nucleus to activate transcription of target genes (Agaisse and 
Perrimon 2004). Two transcription factors STAT A and STAT B have been identified 




of P. berghei while depletion of the JAK/STAT negative regulator, SOCS, decreased 
infection (Gupta et al. 2009). 
Immune Deficiency (IMD) Pathway 
The IMD pathway in Anopheles, has been shown to play a major role in the 
mosquito refractory response to bacteria (Meister et al. 2005) and Plasmodium 
(Richman et al. 1997; Osta, Christophides & Kafatos 2004; Meister et al. 2005; Garver 
et al. 2009; Garver et al. 2012; Meister et al. 2009; Pike et al. 2014; Cirimotich et al. 
2010;  Yassine & M. a Osta 2010). The IMD pathway, can be compared to the tumor 
necrosis factor (TNF) signaling pathway in mammals (Kaneko and Silverman 2005; 
Aggarwal and Silverman 2008). Pathogens detected by peptidoglycan recognition 
proteins (PGRPs) initiate intracellular signaling through the adaptor IMD protein and 
various caspase-like proteins and kinases, leading to a functional split in the pathway 
(Rutschmann et al. 2000; Georgel et al. 2001; Choe et al. 2002; Leulier et al. 2002; 
Leulier et al. 2003; Choe et al. 2005; Kleino et al. 2005; Tanji and Ip 2005). One branch 
is similar to the c-Jun N-terminal Kinase (JNK) pathway of mammals and uses JNK to 
activate the transcription factor AP-1, while the other branch, an NF-kappaB activating 
branch, culminates in the processing of the transcription factor Rel2 (Tanji & Ip 2005b; 
Gupta et al. 2009; Meister et al. 2005; Stoven et al. 2003; Hedengren et al. 1999; 
Dushay et al. 1996; Kallio et al. 2005; Silverman et al. 2000; Stoven et al. 2000; Sluss 
et al. 1996; Hoa & Zheng 2007). The REl2 transcription factor exists as two splice 
variants (Meister et al. 2005; Luna et al. 2006). The constitutively active form Rel2-S 
is a shortened form that lacks the ankyrin inhibitory domain and is responsible for basal 




remains inactive until there is immune signaling (Meister et al. 2005; Luna et al. 2006). 
Activation of the IMD pathway leads to cleavage of the carboxyl terminal end of Rel2-
F and exposes the nuclear localization signal (Meister et al. 2005; Luna et al. 2006). 
Cleaved Rel2-F translocates to the nucleus to initiate transcription of immune factors 
such as leucine rich immune molecule 1 (LRIM1), Anopheles Plasmodium responsive 






 Figure 1.5- Mosquito humoral immune signaling pathways.  In Toll pathway signaling, 
detection of pathogen-derived ligands by PRRs results in Rel1 translocation to the 
nucleus and activate transcription of Toll-pathway regulated genes. The IMD pathway 
is activated by ligand binding to PGRP-LCs and -LEs. This triggers signaling through 
IMD and various caspases and kinases, leading to a functional split in the pathway. One 
branch triggers JNK signaling to activate the transcription factor AP1, while the other 
results in the phosphorylation of transcription factor Rel2. Activated Rel2 translocates 
to the nucleus to activate IMD-regulated transcription. The JAK-STAT pathway is 
triggered by Unpaired (Upd) binding to the receptor Dome, activating the receptor-
associated Hop Janus kinases, which phosphorylate each other and subsequently recruit 
and phosphorylate the STAT transcription factor. Phosphorylated STATs dimerize and 
translocate to the nucleus to activate JAK-STAT-regulated transcription (Adapted from 




 Mosquito Immune Effectors 
 
Analysis of the transcriptional profile of mosquitoes at different stages of the 
Plasmodium infection, especially in the midgut during ookinete invasion has identified 
anti-Plasmodium effector molecules. These effector molecules have mainly been 
characterized through RNAi-based transcript depletion that results in increased levels 
of Plasmodium infection. Further characterization has associated some of these effector 
molecules with specific immune pathways and processes (Cirimotich et al. 2010). 
Although there are a number of anti-Plasmodium effector molecules, only the most 
pertinent ones are covered here. 
 
Thioester-containing protein 1 
Thioester-containing protein 1 (TEP1) is an anti-Plasmodium effector molecule 
and one of the most well studied. TEP1 is involved in range of immune responses 
including phagocytosis, parasite lysis, and melanization (Blandin et al. 2004; Yassine 
& M. A. Osta 2010; Garver et al. 2012; Yassine et al. 2012). Studies have shown that 
it controls both P. berghei and P. falicparum infection in the mosquito midgut (Garver 
et al. 2013; Garver et al. 2009). Blandin et al., 2004 identified TEP1 as the mosquito 
orthologue of complement component 3 (C3) in the human complement system. Recent 
studies have established the role of TEP1 in a highly regulated complement-like 
process in the mosquito, in which TEP1 is deposited on the surface of pathogens 
(Yassine et al. 2014). TEP1 expression is strongly regulated by the IMD pathway 
(Garver et al. 2009). Although there are other Tep molecules in the mosquito, their role 





 Leucine-Rich Immune Molecule 1 
Another important anti-Plasmodium effector molecule is leucine-rich immune 
molecule 1 (LRIM1) that has been shown to control P. berghei (Meister et al. 2005) 
and P. falciparum infections (Garver et al. 2012). Research has shown that TEP1 forms 
complexes with leucine-rich proteins on the surface of parasites, indicating these 
molecules may be involved in the complement-like process (Fraiture et al. 2009; 
Povelones and Waterhouse 2009; Baxter et al. 2010; Povelones et al. 2011). However, 
the principal mechanism behind this finding is not well understood and there are 
possibly many more interacting partners of leucine-rich proteins. 
Leucine-rich repeat (LRR) containing proteins are found in various organisms 
and have been shown to have multiple functions (Povelones and Waterhouse 2009). 
Insects and mammals contain Toll-like receptors involved in initiating an innate 
immune response to pathogens (Vasselon and Detmers 2002). Nucleotide-binding 
oligomerization domain receptors proteins (NOD) in mammals and plants contain LRR 
structures and are involved in immunity and host-defense responses (Loimaranta et al. 
2009). The LRR superfamily is composed of LRR proteins with various domain 
architectures such as Toll receptors with intracellular Toll-interleukin receptor domains 
(Waterhouse et al. 2010). Proteomic analysis of the Anopheles mosquito has identified 
over 180 LRR superfamily members, 24 belonging to the LRIM family which has only 
been identified in mosquitoes (Waterhouse et al. 2010). LRIM family members are 
composed of an N-terminal signal peptide, repeated LRRs that form a horseshoe-like 




2010) (Figure 1.6). LRIM family members that contain all these sequence patterns are 
grouped into the Long LRIM subfamily (Waterhouse et al. 2010). Further LRIM 
subfamilies identified by Waterhouse and colleagues include a short LRIM subfamily 
that contain 6-7 repeated LRR, and Transmembrane LRIM subfamily which have 
predicted C-terminal transmembrane domains. Leucine rich immune molecule 1 is a 
LRR protein found in mosquitoes. LRIM 1 is a member of the long LRIM subfamily 
in mosquitoes. It has been shown to be an effector molecule in the IMD pathway of 
Anopheles mosquitoes and a strong suppressor of parasite development, during low to 
medium infection intensities (Garver et al. 2012) playing a role in both melanization 
(Warr et al. 2006), and lysis  (Jaramillo-Gutierrez et al. 2009), (Habtewold et al. 2008)  
of the parasite. LRIM1 expression in A. gambiae has been demonstrated to be regulated 
by Plasmodium infection with maximum expression coinciding with the movement of 
Plasmodium ookinetes across the basal gut epithelium (Han et al. 2000; Osta, 
Christophides & Kafatos 2004; Marinotti et al. 2005). RNAi studies have demonstrated 
that silencing of LRIM1expression with  dsRNA increased the intensity of Plasmodium 
berghei oocysts infection 3 - 4.5 fold in A. gambiae (Osta, Christophides, and Kafatos 
2004). In similar studies, (O’Brochta et al. unpublished) demonstrated that silencing 
LRIM1 expression in A. stephensi using dsRNA transcribed in vitro using A. gambiae 
LRIM1 as a template increased the number of sporozoites in the salivary glands 2.5 fold  
The present model suggests that LRIM1 functions in a complement-like 
pathway leading to the activation of a C3-like protein, TEP1, that localize to the surface 
of the pathogen, targeting it for destruction (Fraiture et al. 2009), (Povelones and 




APL1 forming a heterodimer (Figure 1.7) that is secreted into the hemolymph. The 
LRIM1/APL1 complex then binds to a mature cleaved TEP1 molecule stabilizing it 
and promoting binding to the pathogen surface (Fraiture et al. 2009; Waterhouse et al. 





Figure 1.6- Structure of LRIM family members. Members of the LRIM family are 
characterized by four structural patterns. An N-terminal signal peptide; repeated LRR 
which form a horseshoe like structure; a pattern of cysteine residues, and a coiled coil 
domain region. Further sub-families includes Transmembrane LRIMs which have 
predicted C-terminal transmembrane domains and Coil-less LRIMs with all the 















Figure 1.7- Crystal structure of the LRIM1/APL1C heterodimer. The LRIM1/APL1C 
heterodimer is secreted into the hemolymph where it bind to a cleaved TEP1 molecule 
stabilizing it. The TEP1/LRIM1/APL1C complex bind to the surface of foreign bodies 
or pathogens targeting them for destruction by the immune system. (Adapted from PDB 




 Summary and rationale of dissertation research 
 
In the first part of this work I investigate the immune response of Plasmodium 
susceptible Anopheles stephensi Sda500 to infection by Plasmodium falciparum NF54. 
The mosquito immune response to Plasmodium has been demonstrated to be dominated 
by IMD pathway effector molecules in Plasmodium refractory strains of A. gambiae 
and A. stephensi. Sanaria’s vaccine manufacturing platform utilizes the laboratory 
derived strain of A. stephensi which was selected for its susceptibility to Plasmodium 
infection. Since the aim of the project is to attenuate the immune response to increase 
sporozoite infection in the salivary glands, the immune response  and specifically the 
IMD pathway response in A. stephensi Sda500 is assessed during Plasmodium and 
bacterial infection. After identifying homologs of IMD effector genes in A. stephensi I 
used real-time quantitative PCR to assess gene expression during infection. The unique 
findings demonstrate an IMD immune response to Plasmodium infection and may 
indicate the regulation of IMD effector genes by different pathways.   
In the second part of this work I explore the use of the Gal4/UAS bi-partite 
system for stable gene knockdown using shRNA. Due to strict manufacturing 
protocols, injecting mosquitoes with dsRNA is not feasible, therefore a stable 
transgenic mosquito line with regulated silencing cassettes is developed. The 
Gal4/UAS system is commonly used in Drosophila and has been recently adapted for 
use in mosquito. However work to date has not used the system for gene knockdown 
in mosquitoes. I designed a plasmid containing an inverted repeat of a region of LRIM1 
under the regulatory control of UAS and inserted it into the genome of A. stephensi 




adaptation of the Gal4/UAS system for spatial and temporal gene silencing in 
mosquitoes.  Infection studies of transgenic mosquitoes demonstrated that silencing of 
LRIM1 can increase sporozoite infection in the salivary glands and therefore these 
transgenic mosquitoes are excellent candidates for being incorporated into the 
sporozoite and vaccine production process at Sanaria Inc. 
  In the third part of this work I identify and clone the LRIM1 promoter region to 
identify the tissues where LRIM1 is expressed. This could allow for targeted 
knockdown of LRIM1 expression to increase sporozoite infection in the salivary glands. 
The current model of LRIM1 function proposes that LRIM1 is expressed in the fat body, 
midgut and hemocytes of A. gambiae. However, microarray experiments of A. gambiae 
have shown evidence of LRIM1 expression in the head, salivary glands, ovaries and 
malpighian tubules of adult females. It is therefore unclear exactly where and when 
LRIM1 is expressed and how this relates to its purported function. Here, I attempt to 
determine the spatial and temporal pattern of LRIM1 expression by creating transgenic 
mosquitoes that will make use of the bi-partite Gal4::UAS system to control the 









Chapter 2: Validation of Anopheles stephensi LRIM1 as a viable 
target for immune system modification in Sda500 
 
 Introduction 
Development of a live-attenutated Plasmodium falciparum sporozoites vaccine 
for malaria was thought to be clinically impractical for three primary reasons: (1) 
Sporozoites would need to be delivered alive to be effective; (2) the vaccine would 
need to be stable, aeseptic and cryopreservable, and (3) the difficulty of efficiently 
generating sufficient sporozoites for vaccine manufacturing (Hoffman et al. 2010). 
Presently, Sanaria Inc. has addressed the challenge of vaccine delivery by developing 
a clinically accepted intravenous route for vaccine administration, and they have also 
developed a proprietary method for rearing aseptic mosquitoes to produce stable, 
aseptic sporozoites that are cryopreservable. However vaccine production still remains 
an expensive, labor intensive process and is expected to directly impact vaccine cost 
(Sanaria Inc.). To produce the vaccine, sporozoites are taken directly from the salivary 
glands of infected female mosquitoes, therefore directly linking vaccine production to 
salivary gland infection intensity and prevalence (Sanaria Inc.). The mosquito’s 
immune system plays a major role in limiting the parasite’s development and the 
infection intensity of sporozoites. (Cirimotich et al. 2010; Hillyer 2010). Therefore, we 
hypothesized that modifying the immune system of the mosquito to increase salivary 
gland infection intensity would increase vaccine production and lower its cost. 
The Immune Deficiency (IMD) pathway in Anopheles, has been shown to play 
a major role in the mosquito’s immune response to Plasmodium falciparum (Cirimotich 




blood meal. During development in the mosquito, the number of parasites can be 
reduced by as much as 107 fold by the innate immune system (Alavi et al. 2003; Hillyer 
2010).  
LRIM 1 is an effector molecule in the IMD pathway of Anopheles mosquitoes 
and has been shown to be a strong antagonist of parasite development during low to 
medium infection intensity (Garver et al. 2012) and plays a role in both melanization 
(Warr et al. 2006), and lysis  (Jaramillo-Gutierrez et al. 2009; Habtewold et al. 2008)  
of the parasite. RNA interference (RNAi) studies have demonstrated that silencing 
LRIM1 expression with  dsRNA increased the intensity of Plasmodium berghei 
infection 3 - 4.5-fold in A. gambiae as reflected in the number of oocysts (Osta, 
Christophides, and Kafatos 2004). In similar studies, O’Brochta et al. (unpublished) 
demonstrated that silencing LRIM1 expression in A. stephensi using dsRNA transcribed 
in vitro using A. gambiae LRIM1 increased the number of sporozoites in the salivary 
glands 2.5-fold.  
The laboratory strain Anopheles stephensi Sda500 is the mosquito used as 
Sanaria Inc’s  manufacturing platform due to its high susceptibility to Plasmodium 
infection, consistently having 2-fold higher infection intensity, compared to Sind 
strains (Feldmann et al. 1990). The mechanism for its increased susceptibility is 
presently unknown, but could be a result of mis-regulation of the IMD pathway which 
could make the IMD pathway a poor target for genetic modification in this strain. 
Furthermore, previous studies looking at the effects of LRIM1 on parasite survival have 




Anopheles species. Therefore it is unclear whether LRIM1 would be good target for 
increasing the susceptibility of A. stephensi to Plasmodium falciparum.  
The aim of this project was to test the validity of A. stephensi LRIM1 as a viable 
candidate for immune modification by identification and cloning of A. stephensi LRIM1 
and examining the expression pattern of A. stephensi LRIM1 under challenge with 
Plasmodium falciparum and E. coli. 
 Materials and Methods 




Cloning of Anopheles stephensi Sda500 Leucine Rich Immune Molecule 1  
Anopheles stephensi Sda500 cDNA was generated by in vitro reverse 
transcription of A. stephensi Sda500 RNA was used as the template in a polymerase 
chain reaction (PCR) using primers AsLRIM1fw (5’ - CCC GCC GGT ATA GCT TAT 
CAG – 3’) and AsLRIM1rv (5’- CAA ATA GTG CTC GTC TGC GC - 3’) that were 
designed based on a known A. gambiae LRIM1 sequence aligned to an assembled draft 
genome sequence of A. stephensi created by Dr. Zhijian Tu at Virginia Polytechnic 
Institute and State University, Blacksburg VA 24061. Polymerase chain reaction 
generated a 1.8 kilobase fragment. Nucleotide pairwise sequence alignment to the 
known A. gambiae LRIM1 sequence showed 58 percent sequence identity. Amino acid 
pairwise alignment (Clustal Omega) showed 60 percent amino acid identity of                        
A. stephensi LRIM1 to A. gambiae LRIM1. Further sequence analysis using LRR finder 




acid residues(Figure 2.1). Marcoil analysis (Delorenzi and Speed 2002) with a 99% 
threshold identified two coiled coil domains in the region of amino acid residues 318 
to 366 and 424 to 459 (Figure 2.1). SignalP-4.0 (Petersen et al. 2011) identified a signal 
peptide region from residue 1 to 19 (Figure 2.1). Further analysis using the most current 
A. stephensi genome release, VB-2015-10, AsteS1 (Jiang et al. 2014) identified our 






















Figure 2.1- Anopheles stephensi Sda500 LRIM1. Amino acid sequence of LRIM1 
isolated and cloned from Anopheles stephensi Sda500. Characteristic feature of the 
leucine rich immune molecule family are shown. Signal peptide region-grey; leucine 















Immune Response of A. stephensi Sda500 to Plasmodium falciparum infection 
The carcass (all tissue remaining after removal of the midgut) and midgut of 
female A. stephensi were assessed for IMD pathway immune response at 24-26; 48-50; 
and 72-74 hours post blood feed infection. Using qRT-PCR, transcript levels of IMD 
effector genes LRIM1, APLIC and TEP1 and also IMD pathway negative regulator 
Caspar were assessed in mosquitoes provided a Plasmodium falciparum infected blood 
meal, or a non-infected blood meal. Naïve mosquitoes maintained on 10% sucrose were 
used as controls. (Here, changes referred to as “modest” are significant but lower than 
2 fold) 
 
IMD Pathway Immune Response in Carcass 
Between 24 to 26 hours post blood feed the transcript levels of LRIM1, APLIC 
and TEP1 were specifically up-regulated in mosquitoes provided infected blood and 
non-infected blood compared to control mosquitoes maintained on sucrose. Average 
LRIM1 expression in infected blood and non-infected blood-fed mosquitoes were 
respectively 5 and 2-fold greater than controls. APLIC and TEP1 had average increases 
greater than 3-fold in Plasmodium infected mosquitoes compared to control 
mosquitoes, while there were modest increases in APL1C and TEP1 in non-infected 
blood fed mosquitoes. Average Caspar transcript levels were lower in both infected 
and non-infected blood fed mosquitoes compared to control naïve mosquito (Figure 
2.2).  
In mosquitoes assessed 48 to 50 hours post blood feed, transcript levels of 




blood fed females compared to controls. However Caspar transcript levels in both 
infected and non-infected blood fed females were on average more than 4-fold higher 
than in comparable naïve sucrose maintained females (Figure 2.3).  
Assessment of mosquitoes 72 to 74 hours post blood feed showed that transcript 
levels of Caspar decreased in both infected and non-infected blood fed mosquitoes but 
remained over 2 folds higher than controls. LRIM1 transcript levels in both blood fed 
groups remained lower than in controls. APL1C and TEP1 transcript levels were also 
lower in infected blood fed females compared to controls, however in females fed non-






















Figure 2.2 Transcript levels of LRIM1, APL1C, TEP1 and Caspar in the carcass of                
A. stephensi females 24 -26 hours post Plasmodium falciparum infection. The carcass 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Transcript levels are reported as a 
fold expression compared to naïve non-blood fed females. Error bars indicate 






Figure 2.3- Transcript levels of LRIM1, APL1C, TEP1 and Caspar in the carcass of      
A. stephensi females 48-50 hours post Plasmodium falciparum infection. The carcass 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Transcript levels are reported as a 
fold expression compared to naïve non-blood fed females. Error bars indicate standard 






Figure 2.4- Transcript levels of LRIM1, APL1C, TEP1 and Caspar in the carcass of      
A. stephensi females 72-74 hours post Plasmodium falciparum infection. The carcass 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Transcript levels are reported as a 
fold expression compared to naïve non-blood fed females. Error bars indicate standard 




IMD Pathway Immune Response in Midgut 
Similar to transcript levels observed in the carcass, midgut transcript levels of 
LRIM1, APL1C and TEP1 were higher in infected and non-infected blood-fed females 
compared to controls. However the fold increase observed in the midgut was lower 
than the upregulation observed in carcass 24 -26 hours post blood feed (Figure 2.6). 
Both blood fed groups had elevated Caspar transcript levels when compared to the 
controls, with the transcript abundance in infected blood fed females trending lower. 
Between 48 to 50 hours the expression pattern in the midgut paralleled the 
expression observed in the carcass with increased Caspar and lower LRIM1, and 
APL1C transcripts compared to controls. TEP1 transcript levels were marginally but 
not significantly higher in both blood fed groups compared to controls. Caspar 
transcript levels in infected and non-infected blood females were more than 3 and 2-
fold higher respectively (Figure 2.7). 
Between 72 to 74 hours post blood feed Caspar transcript levels fell in both 
blood fed groups but was still more than 2-fold higher than observed in controls. TEP1 
transcript levels in both blood fed groups were modestly higher than the controls, while 
transcript levels of LRIM1 and APL1C in both blood fed groups were lower than the 










Figure 2.5- Transcript levels of LRIM1, APL1C, TEP1 and Caspar in the midgut of      
A. stephensi females 24-26 hours post Plasmodium falciparum infection. The midgut 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Transcript levels are reported as a 
fold expression compared to naïve non-blood fed females. Error bars indicate standard 






Figure 2.6- Transcript levels of LRIM1, APL1C, TEP1 and Caspar in the midgut of      
A. stephensi females 48-50 hours post Plasmodium falciparum infection. The midgut 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Transcript levels are reported as a 
fold expression compared to naïve non-blood fed females. Error bars indicate standard 






Figure 2.7- Transcript levels of LRIM1, APL1C, TEP1 and Caspar in the midgut of      
A. stephensi females 72-74 hours post Plasmodium falciparum infection. The midgut 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Transcript levels are reported as a 
fold expression compared to naïve non-blood fed females. Error bars indicate standard 




Immune Response 14 days post infection in salivary glands 
The salivary glands of infected females were assessed for IMD pathway 
response fourteen days post Plasmodium infection. This time point in the parasite life 
cycle, corresponds to salivary gland invasion by sporozoites.  Both APL1C and TEP1 
showed greater than 2-fold increase in average transcript levels when compared to 
mosquitoes that fed on non-infected blood while LRIM1 showed a 1.8-fold increase 
when compared to controls. There was also a modest but significant 1.3-fold increase 




















Figure 2.8- Transcript levels of LRIM1, APL1C, TEP1 and Caspar in the salivary 
glands of A. stephensi females 14 days post Plasmodium falciparum infection. The 
salivary glands of 30 individual females were pooled and RNA extracted. Gene 
expression was measured as described in Materials and Methods. Transcript levels are 
reported as a fold expression compared to non- infected blood fed females. Error bars 




Response of Anopheles stephensi Sda500 IMD pathway to Escherichia coli 
infection 
To assess the role of the IMD pathway in response to infection by gram negative 
bacteria, four days old females were treated with E. coli via injections or through 
feeding.  Transcript levels of LRIM1, APL1C, TEP1 and IMD pathway transcription 
factor Rel2 were assessed in the whole body of E.coli or PBS treated mosquitoes 24 
hours post infection (Figure 2.9). All the genes assessed showed no upregulation in 
response to E. coli infection. Similar results were observed when LRIM1 transcript 
levels were assessed 24 hours after mosquitoes were provided an artificial feeding 


















Figure 2.9- Transcript level of IMD pathway effector molecules and IMD pathway 
transcription factor Rel2 in the whole body of A. stephensi females 24 hours post E. 
coli  infection. The carcass of 10 individual females were pooled and RNA extracted. 
Gene expression was measured as described in Materials and Methods. Transcript 
levels are reported as a fold expression compared to naïve non-infected females. Error 





Figure 2.10- LRIM1 transcript level in response to infection by gram-negative E. coli 
(100 CFU/ml) in sterilized artificial feeding buffer 24 hours post infection. The whole 
body of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Transcript levels are reported as a 
fold expression compared to naïve non-injected females. Error bars indicate standard 







Anopheles stephensi LRIM1 is a member of the long LRIM sub-family 
Analysis of the LRIM1 homolog isolated from A. stephensi identified it as 
member of the LRIM family. Like LRIM1 previously described in A. gambiae, A. 
stephensi A. stephensi Sda500 LRIM1 exhibited the conserved double coiled coil             
C-terminal domain (Waterhouse et al. 2010). These coiled coil domains are thought to 
facilitate the protein/protein interactions of LRIM1 and APL1 which form a 
heterodimer complex within the complement-like immune response (Povelones and 
Waterhouse 2009). Mosquito LRIMs are characterized by a variable number of 6 to 14 
leucine-rich repeats, which distinguishes the short and long subfamily of LRIMs 
(Waterhouse et al. 2010). The short LRIM subfamily contains 6 to 7 leucine-rich 
repeats while the long LRIM subfamily contains 10 or more leucine-rich repeats 
(Waterhouse et al. 2010). The previously identified A. gambiae LRIM1 is characterized 
as a long LRIM with 10 LRRs. The LRIM1 gene isolated from A. stephensi had 9 LRRs 
predicted using LRRfinder and therefore also a long LRIM  
An N-terminal signal peptide was predicted in LRIM1 isolated from A. gambiae 
and A. stephensi. This would suggest that LRIM1 is secreted from cells. However 
previous studies by (Povelones and Waterhouse 2009; Povelones et al. 2011) suggest 
that the Anopheles gambiae LRIM1 monomer is only secreted into the hemolymph, 
after the formation of the LRIM1/APL1 complex. In both AsLRIM1 and AgLRIM1 
between the C-terminal coiled coil domain and the leucine-rich repeats is a conserved 
double cysteine motif. This motif has been implicated in the formation of the disulfide 






Plasmodium falciparum infection regulates LRIM1 expression in female 
Anopheles stephensi 
It has been previously reported that LRIM1 in A. gambiae functions as a strong 
suppressor to Plasmodium berghei development, (Warr et al. 2006; Habtewold et al. 
2008; Gutierrez et al. 2009). Post blood meal or P. berghei infection the expression of 
LRIM1 in A. gambiae significantly increases (Marinotti et al. 2006) with highest 
expression levels observed 24 hours after infection when ookinetes are traveling across 
the basal lamina of the mosquito midgut (Osta, Christophides, and Kafatos 2004). Later 
studies by Mendes et al. (2011) demonstrated that the midgut immune response, 
specifically the IMD pathway response, during A. gambiae infection by P. falciparum 
was infection intensity dependent with 972 genes regulated during low infection 
intensity (<15 oocysts in midgut) compared to 557 during high infection intensity (>15 
oocyst in the midgut). This observation was later supported by (Garver et al. 2012) who 
reported on the novel intensity dependent role of LRIM1 during P. falciparum 
infections in A. gambiae.  
Our studies demonstrated that A. stephensi Sda500 that were provided a  
P. falciparum infected blood meal had significant increases in IMD effector molecules 
expression 24 -26 hours post infection compared to controls. However, the relatively 
small increase in transcript abundance in the midgut may support previous observations 
by Mendes et al. (2011) and Garver et al. (2012) of infection intensity dependent IMD 
pathway signaling in the midgut. Our observation of maximum LRIM1 expression 24 





also paralleled previous studies by Osta et al. (2004) and Marinotti et al. (2005) 
studying A. gambiae response to P. berghei infection. The relationship shown here 
between A. stephensi IMD pathway and Caspar expression corresponded to previous 
observations (Garver et al. 2012) in their study of the relationship between the negative 
regulator Caspar and the IMD pathway response to Plasmodium. These observations 
along with the IMD pathway response to P. falciparum infection indicates that the IMD 
signaling pathway in A. stephensi Sda500 is induced in response to parasites.  
 
Role of the A. stephensi salivary glands in Plasmodium defense  
The novel observation of a statistically significant increase in expression of 
IMD effector genes in the salivary glands fourteen days post P. falciparum infection 
could provide significant insight into the mosquito’s defense against the parasite. It is 
the prevailing thought that the humoral response against the parasite is concentrated in 
the midgut, but this new observation may suggest other tissues invaded by the parasite 
also mount an immune response. Unpublished studies by O’Brochta and colleagues 
where they observed that silencing LRIM1 had no effect on P. falciparum oocyst 
intensity but increase sporozoite intensity 2.5 fold compared to control mosquitoes 
could support a post midgut immune response by IMD pathway immune effectors to 
Plasmodium. Future studies to elucidate the role of specific tissues in parasite defense 








IMD pathway in Anopheles stephensi Sda500 was not regulated by E. coli  
infection 
 
Previous studies have demonstrated the role of the IMD pathway (Dimopoulos 
et al. 1997; Dimopoulos et al in 2002) and specifically the role of TEP1 (Waterhouse 
et al. 2010; Yassine et al. 2014) in defense against E. coli  in A. gambiae. In our attempt 
to upregulate the IMD pathway by injection of E. coli directly into the body cavity of 
the mosquito or introduction through feeding, there was no significant difference 
observed in the expression of genes involved in the mosquito complement like immune 
system. Further analysis of the IMD pathway transcription regulator Rel2 also showed 
no significant difference in its level of expression following injection or feeding on      
E. coli compared to the control. Further studies using a wide range of bacteria should 
be performed to determine the role of the IMD pathway in bacterial pathogen defense 
in A. stephensi.  
 
Feeding mechanism can increase LRIM1 expression in A. stephensi 
Studies by Marinotti et al. (2005) and results presented here demonstrated that 
female Anopheles mosquitoes provided with a non-infected blood meal had elevated 
LRIM1 expression compared to non-fed controls. Our studies also demonstrated that 
the upregulation of LRIM1 could be induced by feeding on a solution that did not 
contain blood. Mosquitoes that were provided a sterilized artificial feeding solution  
(Galun 1967) demonstrated modest increase in LRIM1 transcripts compared to sucrose 





conserved mechanism to protect the mosquito from possible harmful pathogens 
ingested during a blood meal similar to the formation the  peritrophic membrane in 
Anopheles mosquitoes after a blood meal (Terra 2001). 
The results presented here demonstrate that A. stephensi Sda500 can mount an 
IMD pathway immune response to Plasmodium falciparum infection. Taken together 
these results show that LRIM1 is a suitable candidate for modification of the innate 
immune system in Anopheles stephensi Sda500 to increase Plasmodium falciparum 





Chapter 3: Transgenic Anopheles stephensi Sda500 bioreactors for 





Production volume and cost of a live attenuated vaccine for malaria is expected 
to be directly correlated with infection intensity of Plasmodium falciparum sporozoites 
in the salivary glands (Sanaria Inc.) Numerous studies (Pike et al., 2014; Garver et al., 
2012; Meister et al., 2005; Osta et al., 2004) have shown that the IMD pathway plays 
a major role in reducing Plasmodium infection intensity in Anopheles mosquitoes. In 
studies aimed at increasing infection intensity in the salivary glands of A. stephensi 
Sda500 and ultimately improving vaccine production, O’Brochta et al. (unpublished) 
demonstrated that silencing expression of the IMD pathway effector gene LRIM1 
increased the infection intensity of sporozoites 2.5 fold. In those studies, LRIM1 gene 
expression in A. stephensi was reduced by RNAi using A. gambiae LRIM1 dsRNA. 
However given the high sequence variation observed among the LRR and coiled coil 
domains of LRIM1 among Anopheles species (Waterhouse et al. 2010), it was 
hypothesized that more effective silencing could be achieved using dsRNA identical to 
A. stephensi LRIM1 and therefore increase sporozoite infection intensity. 
Although those studies demonstrated that sporozoite intensity in the salivary 
glands could be increased by reducing LRIM1 expression with dsRNA, introducing 





aseptic conditions would have the unwanted effect of increasing cost.  It was therefore 
proposed that stable transgenic A. stephensi with a heritable LRIM1 gene silencing 
transgene expressing LRIM1 dsRNA could be used as bioreactors for sporozoite 
production.  A. stephensi is amenable to genetic manipulation and numerous examples 
of transgenic A. stephensi being created using piggyBac transposon-based vectors have 
been reported. (Brown et al. 2003; Catteruccia et al. 2000; Ito et al. 2002; Lycett 2004; 
Nolan et al. 2002; Yoshida & Watanabe 2006; Kim et al. 2004; O’Brochta et al. 2012). 
Furthermore, stable and heritable gene silencing using in vivo-expressed dsRNA has 
been demonstrated in An. stephensi (Brown et al. 2003). A piggyBac transformation 
vector containing the LRIM1 target sequence cloned in an inverted repeat orientation, 
separated by a functional intron can be injected into preblastoderm embryos and 
screened for transgenics. Transcription of this cassette containing an inverted repeat 
fragment of LRIM1 would result in DICER mediated post-transcriptional silencing.  
 Here I propose to use genetic technologies that have rarely if ever been 
used in A. stephensi to create a line of A. stephensi Sda500 with a partially 
dysfunctional immune system. I will combine in vivo expressed shRNA gene silencing 
with the Gal4/UAS binary transcription regulatory system, so that gene silencing can 
be regulated spatially and temporally (Elliott and Brand 2008). This approach will 
enable us to direct silencing of LRIM1 to specific tissues such as the midgut, fat body 
and salivary glands that have been indicated in LRIM1 expression throughout the vector 
stage of the parasite life cycle, thereby eliminating the temporal and spatial limitations 





Gutierrez et al. 2009; Garver et al. 2012) where dsRNA was used to assess the role of 
LRIM1 in the anti-Plasmodium response over a relatively small window of time, our 
approach will help to parse out the role of LRIM1 during the entire vector parasite 
interaction.  
This chapter focuses on the creation and characterization of transgenic A. stephensi 
lines that express stable hairpin RNA from transgenes integrated into the genome 
targeting LRIM1 and the analysis of these lines for the increased susceptibility to 
Plasmodium.  
 Materials and Methods 
Materials and Methods can be found on page 102 
 Results 
 
Transient silencing of A. stephensi LRIM1 with dsRNA  
Silencing of LRIM1 expression in the whole body of A. stephensi Sda500 
females was assessed 4 days post dsRNA injection by quantitative reverse transcription 
polymerase chain reaction (qRTPCR) (Figure 3.1). Compared to control mosquitoes 
injected with dsEGFP, mosquitoes injected with dsAgLRIM1 and dsAsLRIM1 had 
average transcript abundance of 78.8% ± 7.1% and 53.5% ± 12.1% respectively. 
 
Transient silencing of A. stephensi LRIM1 with dsAsLRIM1 reduces lifespan. 
 Adult female A. stephensi Sda500 injected with dsAsLRIM1 RNA showed a 





(figure 3.2). On average 100 percent of dsAsLRIM1 injected females were dead 10 
days post injection, compared to only 66 and 68 percent fatality in dsEGFP and 
dsAgLRIM1 injected females respectively.  In all injected groups there was 





Figure 3.1- Transcript levels of LRIM1 in the whole body of A. stephensi Sda500 
females four days post dsRNA injection to silence LRIM1 expression. The whole body 
of five females from each injection were pooled and RNA extracted. Gene expression 
was measured as described in Materials and Methods. Average transcript abundance is 
shown relative to control dsEGFP-injected mosquitoes. Transcript levels of ribosomal 
S7 gene were used as a calibrator. Bars indicate standard error of the mean of three 






Figure 3.2- Survival of A. stephensi females after injection of dsRNA to silence LRIM1 
expression. A. stephensi Sda500 females injected with dsAsLRIM1 had 100 percent 
fatality 10 days post injection compared to 66 percent and 68 percent fatality of 
dsEGFP and dsAgLRIM1 injected controls respectively. 50 female mosquitoes were 






Characterization of LRIM1-silencer lines 
Transgene insertion site 
Three LRIM1 silencer lines; LRIM1-silencer F2, LRIM1-silencer M2 and LRIM1-
silencer M7 (Figure 3.3), were created as described in the Material and Methods. Here 
we refer to lines LRIM1-silencer F2, LRIM1-silencer M2 and LRIM1-silencer M7 as 
F2, M2 and M7 respectively. Cytogenetic location of the transgene insertion site was 
determined using Splinkerette PCR and chromosomal location data of A. stephensi 
scaffolds provided by Igor Sharakov of Virginia Polytechnic Institute and State 
University. Integration site for F2 was determined to be in the intergenic region of 
scaffold KB664543 on Chromosome 3R. For M2 the transgene was found in the 
intergenic region of scaffold KB664524 located on Chromosome 2R while the M7 
transgene was located in the intergenic region of scaffold KB664832 located on 















Table 3.1- Cytogenetic location of the LRIM1 silencing transgene in the A. stephensi 
genome.  
 Insertion site 
Silencer line  Scaffold  Chromosome 
   
LRIM1-silencer F2 KB664543 3R 
LRIM1-silencer M2 KB664524 2R 





















Figure 3.3- Silencer lines LRIM1-silencer F2, LRIM1-silencer M2 and LRIM1-
silencer M7. (A) Dorsal view of whole third-instar larva showing nlsEGFP marker gene 
expression. (B) Ventral view of whole third-instar larva showing nlsEGFP marker gene 














in vivo dsRNA silencing LRIM1 in transgenic Anopheles stephensi 
The progeny of the UAS:LRIM1-silencer lines were crossed with the MB24 
Gal4 driver line (O’Brochta et al 2012) which expresses Gal4 in the midgut, fat body 
and salivary gland (see appendix). Progeny containing a copy of UAS::LRIM1-silencer 
and Gal4 were used to test for tissue specific silencing of LRIM1 expression using 
qRTPCR. The abundance of LRIM1 transcript in each genotype was compared to 
transcript abundance in the wildtype. Progeny that contained a single transgene element 
showed no statistically significant difference in LRIM1 transcript abundance in tissues 
examined compared to wildtype. Progeny of the three silencer lines (F2, M2 and M7) 
that contained both the Gal4 and UAS::LRIM1-silencer elements showed reduction of 
LRIM1 transcript abundance in the midgut, salivary gland and carcass (midgut and 
salivary glands removed) compared to wild type. In the midgut the average transcript 
abundance was reduced to 72% ± 6.0%, 65% ± 9.6% and 52% ± 6.2% (Figure 3.4 – 
3.6) for lines F2, M2 and M7 respectively. Meanwhile the average carcass transcript 
levels in F2, M2 and M7 were reduced to 64% ± 13.2 %, 65% ± 7.4% and 63% ± 10.8% 
respectively (Figure 3.7 – 3.9)  
Comparison among the 3 lines showed there was no statistical difference in 
LRIM1 expression in the carcass (Figure 3.13), however analysis of the midgut and 
salivary gland showed that the transcript reduction in M7 was statistically significant 
compared to the other lines (Figures 3.14 & 3.15). For both the M2 and M7 lines 
transcript reduction was greater in the salivary glands with average transcript 
abundance of 56% ± 8.3% and 38% ± 4.1% respectively. Average transcript abundance 





                                                                                                                                                  
Figure 3.4- Transcript abundance of LRIM1 in the midgut of GAL4::LRIM1-silencer 
F2 females 24 -26 hours post blood meal compared to controls. For each genotype the 
midgut of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Average transcript abundance is 
shown relative to wild type mosquitoes. Transcript levels of ribosomal S7 gene were 













Figure 3.5- Transcript abundance of LRIM1 in the midgut of GAL4::LRIM1-silencer 
M2, 24 -26 hours post blood meal compared to controls. For each genotype the carcass 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Average transcript abundance is 
shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 






Figure 3.6- Transcript abundance of LRIM1 in the midgut of GAL4::LRIM1-silencer 
M7 females 24 -26 hours post blood meal compared to controls. For each genotype the 
midgut of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Average transcript abundance is 
shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 












Figure 3.7- Transcript abundance of LRIM1 in the carcass of GAL4::LRIM1-silencer 
F2, 24 -26 hours post blood meal compared to controls. For each genotype the carcass 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Average transcript abundance is 
shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 






Figure 3.8- Transcript abundance of LRIM1 in the carcass of GAL4::LRIM1-silencer  
M2, 24 -26 hours post blood meal compared to controls. For each genotype the 
carcass of 10 individual females were pooled and RNA extracted. Gene expression 
was measured as described in Materials and Methods. Average transcript abundance 
is shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 






Figure 3.9- Transcript abundance of LRIM1 in the carcass of GAL4::LRIM1-silencer 
M7, 24 -26 hours post blood meal compared to controls. For each genotype the 
carcass of 10 individual females were pooled and RNA extracted. Gene expression 
was measured as described in Materials and Methods. Average transcript abundance 
is shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 












Figure 3.10- Transcript abundance of LRIM1 in the salivary glands of GAL4::LRIM1-
silencer F2, 14-15 days post blood meal compared to controls. For each genotype the 
carcass of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Average transcript abundance is 
shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 












Figure 3.11- Transcript abundance of LRIM1 in the salivary glands of GAL4::LRIM1-
silencer M2, 14 -15 days post blood meal compared to controls. For each genotype the 
carcass of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Average transcript abundance is 
shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 












Figure 3.12- Transcript abundance of LRIM1 in the salivary glands of GAL4::LRIM1-
silencer M7, 14-15 days post blood meal compared to controls For each genotype the 
carcass of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Average transcript abundance is 
shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 












Figure 3.13- Comparison of LRIM1 transcript abundance in the carcass of 
GAL4::LRIM1-silencer lines 24 -26 hours post blood meal. For each line the carcass 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Average transcript abundance is 
shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 











Figure 3.14- Comparison of LRIM1 transcript abundance in the midgut of 
GAL4::LRIM1-silencer lines 24 -26 hours post blood meal. For each line the carcass 
of 10 individual females were pooled and RNA extracted. Gene expression was 
measured as described in Materials and Methods. Average transcript abundance is 
shown relative to wild type. Transcript levels of ribosomal S7 gene were used as a 











Figure 3.15- Comparison of LRIM1 transcript abundance in the salivary glands of 
GAL4::LRIM1-silencer lines 14-15days post blood meal. For each line the carcass of 
10 individual females were pooled and RNA extracted. Gene expression was measured 
as described in Materials and Methods. Average transcript abundance is shown relative 
to wild type. Transcript levels of ribosomal S7 gene were used as a calibrator. Bars 





in vivo dsRNA silencing of LRIM1 in A. stephensi Sda500 does not reduce lifespan 
In our previous experiments it was shown that dsAsRNA injected into adult      
A. stephensi Sda500 females reduced their lifespan. To determine if in vivo shRNA 
silencing with a smaller and more specific target site would have a similar phenotype 
as injecting dsRNA, the life span of the progeny generated from crossing LRIM1-
silencer/- lines with the MB24 Gal4/- driver line was assessed. No statistical difference 
was observed in the life span of the progeny when any of the three silencer lines were 
crossed with Gal4 driver line (Figure 3.16 – 3.18). 
 
in vivo dsRNA silencing of A. stephensi LRIM1 in females showed no difference in 
midgut bacterial load. 
 To study the response of the gut microbiota to LRIM1 silencing the bacterial 
load in the midgut of progeny from the cross of LRIM1silencer M7 with MLB24-Gal4 
driver were determined (Figure 3.19) The M7 line was used in this experiment because 
earlier experiments demonstrated greater reduction in midgut expression of LRIM1 
compared to the F2 and M2 lines. No statistical difference was observed in bacterial 
load of the genotypes examined. The average Colony Forming Unit (CFU) in the 











Figure 3.16- Survival comparison of the progeny from a cross of LRIM1-silencer F2 
with the MLB24 Gal4 driver line. Fifty female pupae from each genotype were pooled 
in a cage and observed for 21 days post emergence. The cage was examined daily and 
dead individuals were removed and the genotype determined. No statistical difference 














Figure 3.17- Survival comparison of the progeny from a cross of LRIM1-silencer M2 
with the MLB24 Gal4 driver line. Fifty female pupae from each genotype were pooled 
in a cage and observed for 21 days post emergence. The cage was examined daily and 
dead individuals were removed and the genotype determined. No statistical difference 














Figure 3.18- Survival comparison of the progeny from a cross of LRIM1-silencer M7 
with the MLB24 Gal4 driver line. Fifty female pupae from each genotype were pooled 
in a cage and observed for 21 days post emergence. The cage was examined daily and 
dead individuals were removed and the genotype determined. No statistical difference 












Figure 3.19- Midgut bacterial load among the progeny from a cross of LRIM1-silencer 
M7 with MLB24 Gal4 driver. Serial dilutions of midgut homogenate of 10 individual 
females of each genotype were plated on LB agar. CFU was calculated after 48 hour 












Plasmodium falciparum infections 
Plasmodium falciparum Infection experiments were performed using the 
LRIM1-silencer M7 line. Heterozygous LRIM1-silencer M7 females were crossed with 
heterozygous MBL24/Gal4 driver males.  The progeny were fed with Plasmodium 
falciparum infected blood and each genotype was assessed for prevalence, oocyst and 
sporozoite infection, in three replicate experiments (See table 2 for summary of results). 
Seven days post blood feed the mosquitoes were assessed for oocyst infection.  
MBL24Gal4/UAS::LRIM1-silencer mosquitoes expressing the hairpin 
silencing construct had a geomean number of oocyst of 51.3 ± 77.5, 117.8 ± 65 and 
37.5 ± 97.3 for the three respective experiments. Corresponding geomean number of 
oocyts in wildtype individuals were 4.6 – 13 fold lower with counts of 7.1 ± 63.5, 9.0 
± 66.6 and 8.0 ± 37.3. Transgenic mosquitoes with only the GAL4 element or UAS 
LRIM1 silencer element had mean oocyst counts of 49.5 ± 68.2, 26.7 ± 66.3, 30.8 ± 
49.7 and 28 ± 90.5, 23.8 ± 54.2 and 24.5 ± 52.5 respectively. (Figure 3.20) shows the 
pooled data from the three independent experiments. 
Fourteen days PBF the salivary glands of infected mosquitoes were assessed 
for sporozoite infection (Figure 3.21). Mosquitoes expressing the LRIM1 silencer 
construct consistently had 2.5-10 fold higher number of sporozoites in infected salivary 
glands compared to infected wild type salivary gland. Transgenic control, insects with 
only the MBL24 Gal4 transgene or the UAS::LRIM1 transgene consistenly had lower 
sporozoite counts than Gal4::LRIM1-silencer but consistently higher than the wildtype 






Figure 3.20- Plasmodium falciparum infection intensity in A. stephensi Sda500 seven 
days post infection. Circles represent the number of oocysts on a single midgut; 
horizontal black bars represent the median oocysts in each genotype. Three 
independent biological replicates were pooled, and significance was determined by a 







Figure 3.21- Plasmodium falciparum infection intensity in A. stephensi Sda500 
fourteen days post infection. Circles represent the average number of sporozoites from 
a single mosquito; horizontal black bars represent the mean sporozoites in each 
genotype. Salivary glands of 21-25 mosquitoes were dissected and pooled and 













Table 3.2- Summary statistics from Plasmodium falciparum infection assay in figure 
3.20. 
 




























































































































































































































































































































































































































































































Plasmodium bergheii infections 
Plasmodium berghei infection experiments were performed using the LRIM1-
silencer M7 line. LRIM1-silencer M7 females were crossed with heterozygous 
MBL24/Gal4 driver males.  The progeny was provided Plasmodium berghei infected 
mice and each genotype was assessed for prevalence, oocyst and sporozoite infection, 
in two separate experiments (See table 3 for summary of results). Seven days post blood 
feed the mosquitoes were assessed for oocyst infection.  
Gal4::LRIM1-silencer mosquitoes expressing the hairpin silencing construct 
had mean oocyst counts of 60.5 and 17.9 for the two respective experiments (Figure 
3.22-23). Corresponding counts for wildtype individuals were 41.1 and 12.3. 
Transgenic mosquitoes with only the GaL4 transgene or UAS::LRIM1 silencer 
transgene had mean oocyst counts of 44.2, and 13.5 and 36.7 and 12.9 respectively. At 
lower Plasmodium berghei infection intensity indicated by lower oocyts in the midgut, 
transgenic mosquitoes with the MBL24 Gal4 transgene and UAS::LRIM1-silencer 
transgene in their genome had statistically higher Plasmodium infection based on 
Kruskal-Wallis analysis.  
Fourteen days PBF mosquitoes were assessed for sporozoite infection (Figure 
3.24-25). In two independent experiments mosquitoes expressing LRIM1 silencer 
construct consistently had increased sporozoite infection compared to wildtype with 
mean sporozoite counts 1.5 to 2 fold higher. Both transgenic controls (Gal4/+ and 
LRIM1silencer/+) consistently had lower sporozoite counts than Gal4::LRIM1-







Figure 3.22- Plasmodium berghei infection intensity in A. stephensi Sda500 seven days 
post infection. Circles represent the number of oocysts from a single midgut; horizontal 
black bars represent the median oocysts in each genotype. Data represent a single 
experiment. Significance was determined by a Kruskal-Wallis test followed by Dunn’s 









Figure 3.23- Plasmodium berghei infection intensity in A. stephensi Sda500 seven days 
post infection. Circles represent the number of oocysts from a single midgut; horizontal 
black bars represent the median oocysts in each genotype. Data represent a single 
experiment. Significance was determined by a Kruskal-Wallis test followed by Dunn’s 















Figure 3.24- Plasmodium berghei infection intensity in A. stephensi Sda500 fourteen 
days post infection. Bars represent the average number of sporozoites from a single 
mosquito. Salivary glands of 25-30 mosquitoes were dissected and pooled and the 













Figure 3.25- Plasmodium berghei infection intensity in A. stephensi Sda500 fourteen 
days post infection. Bars represent the average number of sporozoites from a single 
mosquito. Salivary glands of 25-30 mosquitoes were dissected and pooled and the 







Table 3.3- Summary statistics from Plasmodium berghei infection assay in figure 3.22- 
3.23. 
 







Exp.1 Gametocytemia 20-24% 20-24% 20-24% 20-24% 
 Prevalence (%) N= 33 93.9 100 100 96.9 
 
Mean oocyst/mosquito 
(Geomean) 41.09 36.73 44.22 60.51 
 sporozoites/mosquito 6,695 4,759 7,133 13,688 
      
Exp.2 Gametocytemia 20-24% 20-24% 20-24% 20-24% 
 Prevalence (%) N= 28 92.8 96.4 96.4 96.4 
 
Mean oocyst/mosquito 
(Geomean) 12.27 12.95 13.55 17.90 








Tissue specific silencing using Gal4/UAS to control in vivo dsRNA expression 
 Reverse genetics approaches and its adaptation to mosquito biology has 
proven to be a crucial tool for dissecting aspects of mosquito biology and the vector 
parasite interaction (Blandin et al. 2002; Catteruccia & Levashina 2009). Transient 
gene silencing by direct injection of dsRNA and stable expression of hairpin RNAs 
from transgenes integrated into the genome are two approaches of RNAi silencing that 
have been established in mosquitoes (Catteruccia & Levashina 2009). However, 
experimental evidence suggests that the efficiency of direct injection of RNAi is limited 
in space and time (Kennerdell and Carthew 1998; Misquitta and Paterson 1999; Brown 
et al. 2003). Constitutive in vivo expression of hairpin RNAs has its own limitations, 
one being the analysis of genes with high fitness costs. In this study we demonstrated 
the adaptation of the bi-partite Gal4/UAS system for control of tissue specific in vivo 
expression of hairpin RNAs in A. stephensi. Using this approach we showed we were 
able to silence LRIM1 expression in the midgut, fat body and salivary glands of A. 
stephensi throughout the entire vector parasite interaction, thereby eliminating the 
temporal and spatial limitations reported with the use of dsRNA injections. Unlike, 
previous studies (Osta, Christophides, & Kafatos, 2004; Jaramillo-Gutierrez et al., 
2009; Garver et al., 2012) where dsRNA was used to assess the role of LRIM1 in the 
anti-Plasmodium response over a relatively small window of time, here we were able 





 Although silencing efficiency using dsRNA to target LRIM1 has been 
reported to be upward of 80% (Osta, Christophides, & Kafatos, 2004; Jaramillo-
Gutierrez et al., 2009) in this study we observed an average silencing efficiency of only 
40% among the different tissues analyzed using three separate LRIM1 silencing lines. 
In an attempt to repeat studies by (Osta, Christophides, & Kafatos, 2004; Jaramillo-
Gutierrez et al., 2009) female mosquitoes injected with dsRNA against A. stephensi 
LRIM1 and A. gambiae LRIM1 had average silencing efficiencies of  46.5% and 21.2% 
respectively. It was also observed that A. stephensi injected with dsRNA against A. 
stephensi Sda500 LRIM1 had reduced life span. This phenotype was not observed in 
mosquitoes expressing in vivo shRNA targeting LRIM1. Possible hypotheses for this 
observations are off target effects of the 500bp dsRNA or an increase in pathogenic 
microbiota in the mosquito in response to LRIM1 silencing.  
LRIM1 silencing did not regulate bacterial load in gut of A. stephensi Sda500 
 Previous studies have demonstrated the role of the IMD pathway 
(Dimopoulos et al. 1997; Dimopoulos et al in 2002) and specifically the role of TEP1 
(Waterhouse et al. 2010; Yassine et al. 2014) in the mosquito defense against bacteria. 
In our studies silencing LRIM1 did not change the bacterial load in the midgut. This 
observation coupled with earlier experiments looking at LRIM1 expression in response 
to E. coli infection could suggest that LRIM1 in A. stephsnsi does not play a role in the 
immune response to bacterial pathogens. However further analysis of the A. stephensi 






Sporozoite infection intensity is increased in transgenic A. stephensi 
 LRIM1 was originally identified as a strong antagonist of Plasmodium 
infection in a rodent malaria model but was subsequently shown to have little 
observable effect on the number  P. falciparum oocyst developing on the basal surface 
of the midgut (Osta, Christophides, and Kafatos 2004; Cohuet et al. 2006). Later work 
revealed that LRIM1 does in fact contribute to the mosquito’s anti-P. falciparum 
response, but only at medium levels of oocyst intensities with little observable effect at 
low intensities (Garver et al. 2012). In our study, transgenic A. stephensi expressing a 
transgene whose transcript formed a short hairpin RNA that lead to the silencing of 
LRIM1 showed a statistically significant increase in oocysts intensity compared to 
wildtype. Further analysis also showed that sporozoite infection intensity was also 
higher in these mosquitoes compared to wildtype. Our data shows that transgenic 
mosquitoes with reduced LRIM1 expression had more oocysts on the basal surface of 
the midgut seven days post infection with Plasmodium falciparum. Similar results were 
observed with lower infection levels of Plasmodium berghei suggesting an infection 
intensity dependent function of LRIM1. In both P. berghei and P. falciparum infections 
mosquitoes with reduced LRIM1 expression consistently had higher sporozoite 
intensities in the salivary glands fourteen days post infection when compared to 
infected controls. Our data shows that transgenic mosquitoes with reduced LRIM1 
expression are excellent candidates for being incorporated into the sporozoite and 





 However, while results here are consistent with earlier findings that 
reduced LRIM1 expression results in increased infection intensity some uncertainty 
remains with regards to the mechanism of increased intensity. Infection data also 
indicated that transgenic mosquitoes that contained only the Gal4 transgene or LRIM1 
silencer transgene had statistically significant increases in both oocyst and sporozoite 
intensity compared to wild type. Therefore, increases observed in mosquitoes with both 
transgenes in their genome could be interpreted as an additive effect of the transgenes 
and not LRIM1 silencing. If  increase in sporozoite intensity is in response to LRIM1 
silencing we believe the difference observed in our data and  previous studies is due to 
the approach used for silencing that allowed targeting of LRIM1 in organs directly 
involved in the parasite development cycle in the mosquito.  
 Overproduction of Gal4 in our MBL24 driver line (Kramer and Staveley 
2003; Lynd and Lycett 2012; Balciuniene et al. 2013) or transgene position (Clark et 
al. 1994; Feng et al. 2001) could affect mosquito fitness and compromise the anti-
Plasmodium response. On the other hand, leaky expression of the hairpin RNA could 
reduce LRIM1 transcripts enhancing Plasmodium susceptibility. 
 Further analysis on the effects transgene integration might exert on the 
immune response is needed before we can attribute increased salivary gland sporozoite 
intensity to LRIM1 silencing. However, average increase in sporozoite intensity (>5 
fold) compared to wildtype Sda500 can significantly impact Sanaria’s manufacturing 











 The current model of LRIM1 function proposes that LRIM1 is expressed in the 
fat body, midgut and hemocytes (Yassine and Osta 2010). However, microarray 
experiments of A. gambiae have shown evidence of LRIM1 expression in the head, 
salivary glands, ovaries and malpighian tubules of adult females (Pinto et al. 2009; 
Baker et al. 2011). Previous microarray methods used to determine the spatial and 
temporal pattern of LRIM1 expression were limited in their resolution and were 
dependent on the quality of tissue collection (Groen 2001). Here, we aim to determine 
the spatial and temporal pattern of LRIM1 expression by creating transgenic                      
A. stephensi Sda500 that will make use of the bi-partite GaL4::UAS system to control 
a fluorescent marker gene. Use of an A. stephensi Gal4 line with Gal4 ORF under 
regulatory control of the LRIM1 promoter, can allow for the spatial, and temporal 
pattern of LRIM1 expression to be assessed visually during pathogenic, non-
pathogenic, and other developmental conditions, when crossed with a responder line, 
containing a fluorescence gene such as TdTomato (Shaner et al. 2004)  under regulatory 
control of UAS.  
Furthermore a transgenic LRIM1 regulated Gal4 line when crossed with an in 
vivo shRNA silencer line like the LRIM1-silencer created here, would target all tissues 
where LRIM1 is expressed. This could significantly reduce the level of LRIM1 






 Materials and Methods 
 




Cloning LRIM1 promoter 
Based on an assembled draft genome of A. stephensi sequence (created and made 
available by Dr. Zhijian Tu at Virginia Polytechnic Institute and State University, 
Blacksburg, VA 24061) a 3.2 kilobase fragment upstream of the predicted LRIM1 ORF 
was amplified using A. stephensi genomic DNA as template and primers LRIM1fw 835 
(5’- GCG AGG ATG ACC CAC TAG AG-3’) and LRIMrv (5’-ATA GGA TCC TAG 
GCG CGC CCC TCC TGA -3’) 
 
Characterization of LRIM1pGal4 lines 
 
Transgene insertion site 
 
Three LRIM1pGal4 lines; LRIMpGal4 M2, LRIMpGal4 M4, and LRIMpGal4 
(Figure 4.1), were created as described in the Material and Methods. (Here we refers to 
lines LRIMpGal4 M2, LRIMpGal4 M4, and LRIMpGal4 as GM2, GM4 and GM8 
respectively). Cytogenetic location of the transgene insertion site was determined using 
Splinkerette PCR and chromosomal location data of A. stephensi scaffolds provided by 
Igor Sharakov of Virginia Polytechnic Institute and State University. Integration site 
for GM2 was determined to be in the intergenic region of scaffold KB665354 on 





KB665343 located on chromosome 3R while the GM8 transgene was located in the 
intergenic region of KB664529. (scaffold location of M8 was undertermined)  For 

























Table 4.1- Cytogenetic location of LRIMpGal4 transgene integration sites in the                    
A. stephensi genome. 
                       Insertion site 
Silencer line  Scaffold  Chromosome 
   
LRIMpGal4 M2 KB665354 2L 
LRIMpGal4 M4 KB665343 3R 

























 Figure 4.1- Transgenic lines LRIMpGal4 M2, LRIMpGal4 M4, and LRIMpGal4. (A) 
Dorsal view of whole third-instar larva showing ECFP expression. (B) Ventral view 
of whole third-instar larva showing ECFP marker gene expression.  (C) Magnification 














Assessment of functional promoter 
Crossing of the LRIM1pGal4 line with a UAS::TdTomato responder line 
(O’Brochta et al. 2012) generated no visible fluorescence response in tissues 
observed. (Figure 4.2) 
  P. bergheii infected A. stephensi Sda500 containing the LRIMpGal4 transgene 
and the UAS::TdTomato transgene where analyzed using qRT-PCR 24 and 72 hours 
post infection to assess native LRIM1 promoter function and transgenic LRIM1 
promoter function. Gal4 expression was used as a proxy for transgenic promoter 
function. 24 hours post infection expression of LRIM1 increased on average 4 fold 
and expression of the transgenic Gal4 increase an average of 3-fold. The expression 





























Figure 4.2- A. stephensi Sda500 with the LRIMpGal4 transgene and UAS::TdTomato 
transgene in the genome. A - Brightfield image; B- DAPI stain showing cell nuclei; 







Figure 4.3- Expression profile of LRIM1 post P. berghei infection showing maximum 
expression 24 hours post infection. Expression is significantly lower 72 hours post 
infection. The activity of the transgenic LRIM1 promoter parallels the endogenous 
LRIM1 promoter and shown by the Gal4 expression. Gene expression was measured as 
described in Materials and Methods. Average transcript abundance is shown relative to 
non-infected transgenic mosquitoes. Transcript levels of ribosomal S7 gene were used 









O’Brochta et al. (2012) showed that the expression of TdTomato in transgenic 
A. stephensi with a gene encoding TdTomato under the control of UAS could be 
regulated using Gal4 driver lines. In my experiments, an LRIM1 regulated Gal4 driver 
line when crossed with a UAS::TdTomato transgenic line did not generate any visible 
TdTomato reponse. However, qRT-PCR data indicated that we were successful in 
cloning a 3.2 kilobases fragment upstream of the ORF of LRIM1 that contains the 
promoter. One hypothesis for no visual TdTomato response being observed is that the 
threshold of TdTomato translated protein needed for it to be visualized under 
fluorescence microscopy is not being achieved. Another hypothesis purports a possible 
conformational change in the Gal4 protein thereby reducing efficient binding to the 
UAS sequence. Lynd and Lycett (2012) have also reported on minimum activity of the 
native Gal4 used in my experiments in mosquito species. Future experiments using 
variants of the Gal4 trans-activator, and assessing threshold activity required for visual 





Chapter 5: Conclusion and Discussion 
 
In the preceding work, I sought to increase the Plasmodium sporozoite intensity 
in the salivary glands in order to enhance vaccine production. Using molecular tools 
rarely, if ever used in A. stephensi Sda500 the overarching goal of the project was 
successfully achieved. 
In chapter 2 Plasmodium infections assays and qRT-PCR were used to 
characterize the response of the IMD pathway effector gene LRIM1 in response to 
parasite infection. These findings lead to the validation of LRIM1 as a suitable target 
for immune modification. However many questions remain. What is the role of the 
salivary gland in response to Plasmodium infection? Are there other pathways for IMD 
signaling and what is the transcription factor? Aside from these remaining questions, 
future directions should include a rigorous biochemical characterization of leucine rich 
repeat proteins. There are also other regulated gene transcripts in the non-pathogenic 
gene response transcriptome awaiting characterization. These studies could provide 
additional targets genes for function studies and translational applications utilizing 
transgenic mosquitoes.  
In Chapter 3, it was confirmed that sporozoite intensity in the salivary glands 
can be increased by using transgenic mosquitoes with modified immune systems. 
While our result are consistent with earlier studies that showed that reducing LRIM1 
expression increased infection intensity some uncertainty remains. These questions 
must be answered to understand the role of LRIM in Plasmodium defense. In the future 





of different tissues in the response to pathogens to be determined. Also an active             
A. stephensi line with the Gal4 ORF under the regulatory control of the LRIM1 





Chapter 6: Materials and Methods 
 
Mosquito strain 
Anopheles stephensi Sda 500 is a laboratory strain of A. stephensi, which was 
first isolated in Pakistan and selected in the laboratory for susceptibility to Plasmodium 
falciparum infection (Feldman et al. 1990) 
Mosquito rearing 
Anopheles stephensi Sda500 mosquitoes were grown in a Conviron 
environmental chamber at 28oC, with 80% relative humidity under a 12-hour light/dark 
cycle. Larvae were fed pulverized fish food (TetraMin Tropical Flakes) ad libitum 
while adults were provided 10% sucrose continuously. Seven day old adult females 
were provided a blood meal of bovine whole blood in acid citrate dextrose (Lampire 
Biological Laboratories, Pipersville, PA) at 37oC through a parafilm membrane on a 
Mosquito Feeder (Chemglass Life Sciences, Vineland, N.J.) for reproduction. Eggs 
were collected in 50 mL of deionized water in a  250 mL Biostor multipurpose 
container (Fisher Scientific), lined with Whatman filter paper (Cat No. 1001 090). 
Artificial feeding buffer 
Artificial feeding buffer composed of 150 mM NaCl; 10 mM NaHCO3 ; 1mM 
Adenosine -5-triphosphate (ATP) (Galun 1967) was substituted for blood in 
experiments were blood could not be used. The solution was fed through a parafilm 





Experimental infection of A. stephensi with P. falciparum 
A. stephensi Sda 500 female mosquitoes were infected with P. falciparum NF54 
by feeding mosquitoes P. falciparum gametocytes in transfusion-quality human 
erythrocytes and serum. Fresh transfusion quality human blood and serum were 
incubated at 37oC. Using aseptic techniques, 1 mL of warm blood was aliquoted into 
an Eppendorf tube and centrifuged for 5 minutes at 2200 RPM. The clear serum was 
discarded and the pelleted erythrocytes were washed with an equal volume of new 
serum three times to obtain the whole blood for the gametocytes. 
Sixteen day old gametocyte culture in RPMI media was removed from the CO2 
incubator and the gametocytemia percent was determined by making a smear on a glass 
slide with one drop of blood. The smear was stained with Giemsa stain (Sigma Aldrich 
48900). The number of gametes in a field of parasite culture was determined, and the 
volume of whole blood needed for a final percent gametocytemia of 0.5 percent was 
calculated.  
Without disturbing the parasite most of the RPMI media was removed from the 
gametocyte culture using a pipette (parasites appear black and media light red/pink). 
The remaining gametocyte culture was transferred to a 15 mL falcon tube (Thermo 
Fisher Scientific Inc. Rockville MD, USA) and centrifuged for five minutes at 2200 
RPM. The supernatant was discarded without disturbing the pelleted gametocytes and 
erythrocytes. The gametocytes were then combined with the required volume of whole 
blood for a final gametocytemia of 0.5 percent. The gametocytes were re-suspended in 





 Three separate cohorts of approximately 400 female wild-type A. stephensi 
were fed Plasmodium falciparum infected blood. Females observed not feeding were 
removed from the cage. Twenty four hours post feeding, 20 mosquitoes with visual 
signs of blood in the midgut were removed from each cohort and anesthetized in cold 
phosphate buffered saline (PBS).The mosquitoes were dissected and the midguts and 
carcasses of the separate mosquito cohorts were immediately flash frozen in RNase 
free tubes on dry ice and pooled for subsequent RNA extraction and real-time PCR. 
This process was repeated 48 and 72 hours post infection. Seven days post infection, 
the midguts of 30 mosquitoes from each cohort were dissected and the oocyst intensity 
determined using Giemsa staining. Fourteen days after blood feeding the salivary 
glands of approximately 20 mosquitoes were dissected and immediately flash frozen 
on dry ice for subsequent RNA extraction. The salivary glands of approximately 30 
mosquitoes were dissected and sporozoite intensity and prevalence determined  
Salivary glands were dissected and kept on ice in 30 µL of RPMI media until 
the dissections were complete. After dissections, the sporozoites were released from 
the salivary glands by aspirating the media containing the salivary glands, five times 
with a 26 gauge, 2 inch point style 3 Hamilton syringe (Reno Nevada, USA).  10 µL of 
the media with sporozoites was transferred to a Bright-Line hemocytometer (Hausser 
Scientific, Horsham Pennsylvania, USA). The hemocytometer was then placed on a 
wet Kimwipe (Kimberly-Clark, Irving Texas, USA) in a petri dish and covered. 
Sporozoites were allowed to settle for 10 to 15 minutes. The number of sporozoites in 






Genomic DNA extraction and quantification 
The following method is a modification of the Ashburner’s method for genomic 
DNA extraction (Ashburner 1989). Mosquito tissue was homogenized in 50 µL of 
homogenization buffer (10 mM Tris-HCL pH 7.5, 10 mM EDTA, 5% sucrose [w/v], 
0.15 mM spermine, 0.15 mM spermidine) and kept on ice. 50 µL of lysis buffer (300 
mM Tris-HCL pH 9.0, 100 mM EDTA, 0.625% SDS [w/v], 5% sucrose [w/v] was 
added to the homogenized mixture, properly mixed and incubated at 70oC for 15 
minutes. The mixture was then cooled to room temperature and 15µL of 8M potassium 
acetate was added and mixed thoroughly. The mixture was then placed on ice for 30 
minutes after which it was centrifuged at 14,000 RPM for 10 minutes at RT. The 
supernatant was transferred to a fresh tube and 90 µL of phenol/chloroform/isoamylic 
alcohol was added and mixed. The mixture was centrifuged at 14,000 RPM at 4oC. The 
supernatant was transferred to a new tube and two volumes of absolute ethanol was 
used to precipitate DNA.  The mixture was centrifuged at 14,000 RPM for 5 minutes at 
RT. The supernatant was discarded and the pellet was washed in 70 % ethanol. After 
centrifuging for 10 minutes at 14,000 RPM the supernatant was discarded and the DNA 
pellet was vacuum dried and suspended in 1× TE buffer pH 7.4. The concentration of 
nucleic acids was determined spectrophotometrically using the NanoDrop ND-1000 
spectrophotometer (NanoDrop, Wilmington, USA) by measuring light absorption at 
260 nm. Nucleic acid purity was checked by determining the absorption at a 







Cloning of Anopheles stephensi Sda 500 Leucine Rich Immune Molecule 1  
Leucine rich immune molecule 1 (LRIM1) was cloned from A. stephensi cDNA 
using Polymerase chain reaction (PCR). LRIM1 was amplified using primers 
AsLRIM1fw (5’ - CCC GCC GGT ATA GCT TAT CAG – 3’) and AsLRIM1rv (5’- 
CAA ATA GTG CTC GTC TGC GC - 3’). To design primers, a known A. gambiae 
LRIM1 sequence (AGAP0006348) was aligned using ApE-A plasmid Editor to an 
assembled draft genome sequence of A. stephensi created and made available by Dr. 
Zhijian Tu at Virginia Polytechnic Institute and State University, Blacksburg, VA 
24061, and now publicly available on VectorBase (Lawson et al. 2007). Conserved 
regions in A. gambiae LRIM1and A. stephensi LRIM1 reported by Jaramillo-Gutierrez 
et al. (2009) were identified. The Open reading frame (ORF) was identified using ORF 
Finder (Wheeler et al. 2003). Primers were designed upstream of the ORF and 
downstream of the stop codon. Phusion High-Fidelity polymerase (New England 
Biolabs (NEB) Ipswich, Mass.) was employed for PCR. LRIM1 PCR product was 
purified by gel electrophoresis and gel extraction (QIAquick gel extraction kit). 
Purified PCR product was inserted into Zero Blunt TOPO PCR Cloning vector 
(Thermo Fisher Scientific Inc., Rockville, MD) according to the manufacturer’s 
instructions and transformed into E. coli  DH10B (Gibco-BRL).  Colonies were 
screened for insertion. Positive colonies were digested with EcoRI and agarose gel 
electrophoresis was used to identify insertion of LRIM1 PCR product. Sequence 







Total RNA extraction and quantification 
 To isolate total RNA from mosquito tissue, Ambion Trizol Reagent was used 
according to the manufacturer’s instructions. To avoid RNase activity, RNase-free 
water and RNase-free reaction tubes were used during the procedure. Briefly, total 
RNA was extracted by homogenizing the tissue in 1 mL of Trizol. The homogenized 
sample was incubated for 5 minutes at room temperature (RT) to allow for complete 
dissociation of the nucleoprotein complex. 0.2 mL of chloroform:isoamyl (49:1) was 
then added to the homogenized sample. The mixture was shaken vigorously by hand 
for 15 seconds and incubated at RT for 3 minutes before centrifugation at 12,000 × g 
for 15 minutes at 4oC. The aqueous phase containing RNA was transferred to a new 
tube. RNA was precipitated with 0.5 ml of 100% isopropanol. The mixture was left at 
RT for 10 minutes before centrifuging at 12,000 × g for 10 minutes at 4oC. The RNA 
pellet was washed with 1 mL of 75% ethanol. After centrifuging at 7,500 × g for 5 
minutes, the wash was discarded and the RNA pellet vacuum dried and suspended in 
RNase-free water. DNase I (RQ1 RNase free DNase – Promega, Cat. No. M610A) 
treatment was done at 37oC for 20 minutes to eliminate any DNA contamination. After 
inactivating the DNase I, the volume of the reaction mix is made up to 50 μL. The 
concentration of nucleic acids was determined spectrophotometrically using the 
NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, USA) by measuring 
light absorption at 260 nm. Nucleic acid purity was checked by determining the 







Reverse Transcription PCR (cDNA synthesis) 
To generate a representative cDNA pool from RNA templates, 1-5 μg of total 
RNA were mixed with 1 µL of oligo(dT)20  primer (50 µM), 10 mM dNTP mix and 
RNase free water to a total volume of 10 μL. To facilitate hybrid formation of the oligo 
dT-primers with polyA-tails of mRNA, the mixture was heated to 65° C for 5 minutes 
and then quickly chilled on ice.  A master mix containing 2 μL of 10X Reverse 
transcriptase (RT) buffer; 4 μL of 25 mM MgCl2; 2 μL of 0.1 M DTT; 1 µL of RNase 
OUT (40 U/µL); 1 µL of Superscript III Reverse transcriptase (RT) (200 U/µL),  was 
added to the mixture: 
The content of the tube was gently mixed and incubated at 50° C for 50 minutes 
for first strand cDNA synthesis. The reaction was then inactivated by incubating the 
mixture at 85° C for 5 minutes and then chilled on ice. After brief centrifugation, 1 µL 
of RNase H was added to the mixture and incubated at 37oC for 20 minutes. The cDNA 
sample was then used for PCR reactions. 
 
Real-time polymerase chain reaction 
Template for the Real-time PCR from cDNA synthesis was diluted to 200 ng. 
All the samples to be compared were processed in parallel and 3 independent 
experiments were performed. PCR reaction was done with 96 well plates (MicroAmp; 
Applied Biosystems; Cat No. N801-0560) covered with optical adhesive covers 
(Applied Biosystems; Cat No. 4313663). The instrument used was an ABI PRISM 
7000 Sequence Detection System (Applied Biosystems). Reaction conditions were as 





52°C for 30 s annealing and 72oC for 15 s extension. Flouresence readings were taken 
at 72oC after each cycle. A final extension of 72oC for 5 minutes was completed before 
deriving a melting curve. Reaction master mix was made with GoTaq colorless master 
mix (Promega, Fitchburg, WI). Primers and templates were added according the 
manufacturer’s instructions. Gene expression was assessed with SYBR green (Life 
Technologies). The reference gene used for the experiments was the ribosomal S7 gene.  
 
Synthesis of dsRNA for LRIM1 silencing 
A cDNA fragment of 500 bp of LRIM1 was amplified using the following 
primers, LRIM1 dsRNAfw (5’- TAA TAC GAC TCA CTA TAG GGA GAC GAC 
TGT ATC TGG CCA ACA ATA - 3’) and LRIM1 dsRNArv (5’- TAA TAC GAC 
TCA CTA TAG GGA GAT CGG TGT CCG TGC ACG CCT CCT - 3’)   with T7 sites 
flanking the 5 prime ends and cDNA template from one week old A. stephensi females 
as template. The resulting PCR fragment was cloned into the pCR II-TOPO vector 
(Invitrogen, Carlsbad, CA) and transformed in E. coli  DH10B (Gibco-BRL). Colonies 
were screened for insertion using restriction enzyme digestion with EcoRI and gel 
electrophoresis. High yield plasmid DNA was isolated using QUIAGEN Plasmid Maxi 
Kit. The T7 flank fragment used for dsRNA synthesized was removed from the plasmid 
by digestion with EcoRI. Double stranded RNA was generated and purified using the 








Silencing Anopheles stephensi LRIM1 and bacterial infection 
Four days old Anopheles stephensi females were anesthetized on ice for 5 
minutes and transferred to a 4oC injection plate. Approximately 100 nL of LRIM1 
dsRNA (3ng/nL) or EGFP dsRNA control was injected into the thorax of the 
mosquitoes using a Pneumatic PicoPump PV820 (World Precision Instrument Inc., 
Sarasota, FL.). After injection the mosquitoes were allowed to recover at RT for one 
hour before being transferred to an environmental chamber (28oC, 80% humidity, and 
12 hour light/dark cycle) (Conviron, Winnipeg, Manitoba) and provided 10% sucrose.  
LRIM1 silencing was confirmed 4 days post dsRNA injection by real-time quantitative 
PCR. For bacterial infections the needle was dipped in a pellet of E. coli (DH10B) 
OD600 of 0.1 and injected into the thorax of the mosquito. For bacterial infections by 
feeding, artificial feeding buffer was inoculated with E. coli to a final CFU of 100 
CFU/ml 
 
Mosquito survival post dsRNA injection 
Three cohorts of 50 four day old adult Anopheles stephensi females were 
obtained. A. stephensi females were anesthetized on ice for 5 minutes and transferred 
to a 4oC injection plate. Approximately 100 nL of LRIM1 dsRNA (3ng/nL) or EGFP 
dsRNA control was injected into the thorax of the mosquitoes using a Pneumatic 
PicoPump PV820 (World Precision Instrument Inc., Sarasota, FL.). After injection the 
mosquitoes were allowed to recover at room temperature (RT) for one hour before 
being transferred to an environmental chamber (28oC, 80% humidity, and 12 hour 





Mosquitoes were observed over the following days and the number of dead mosquitoes 
were recorded. A cohort of 50 un-injected adults A. stephensi females was 
simultaneously observed under the conditions mentioned above. 
 
Survival comparison of transgenic mosquitoes. 
LRIM1-silencer/- lines were crossed with the MB24 Gal4/- driver line. From 
the progeny of the cross, 100 female pupae of each genotype were screened for using 
the fluorescence marker gene. The pupae were pooled, and placed in a one gallon 
mosquito cage. After emergence, the mosquitoes were maintained on a 10 percent 
sucrose solution. The cage was examined each day for dead mosquitoes. The dead 
mosquitoes were screened and scored. 
 
Isolation of midgut microbiota for microbial load assessment. 
Individual A. stephensi Sda500 were surface-sterilized by washing three times 
with alternating 70% ethanol and sterile phosphate-buffered saline (PBS) washes. The 
midguts were then dissected in PBS using flame-sterilized forceps and homogenized 
in 200µl of PBS using a sterilized pestle. Each midgut homogenate was then serially 
diluted and inoculated on Luria-Bertani (LB) agar and incubated at 27oC for 48 hours. 











 This is a piggyBac vector with 672 bases of 5’ terminal and 675 bases of 3’ 
terminal sequences of piggBac containing the Gal4 ORF under the regulatory control 
of the LRIM1 promoter in addition to a marker gene encoding  enhanced cyan 
fluorescent protein (ECFP) under the regulatory control of the 3xP3 promoter 
(Berghammer et al. 1999).  This vector was constructed using Gateway recombination 
cloning technology (Invitrogen, Grand Island, NY), in which 4 recombination modules 
were simultaneously recombined into a destination plasmid. The first module consisted 
of the piggyBac left terminal with gateway recombination site (Invitrogen, Grand 
Island, NY). The second module contained Gal4 ORF under control of the LRIM1 
promoter, the third module consisted of the ECFP marker gene under the regulatory 
control of 3xP3 (Berghammer et al. 1999) and module four contained the piggyBac 
right terminal.  Modules 1, 3 and 4 were present in-house. To make the second module 
a 3.0 kilobase fragment upstream of the LRIM1 ORF was amplified using primers 
LRIM1fw 835 (5’- GCG AGG ATG ACC CAC TAG AG-3’) and LRIMrvAscBam 
(5’-ATA GGA TCC TAG GCG CGC CCC TCC TGA TAA GCT ATA CCG GC-3’) 
with AscI and BamHI restriction sites and inserted into a PCR4-TOPO vector (Thermo 
Fisher Scientific Inc., Rockville, MD). A 3.0 kilobase fragment of Gal4hsp3 was 
amplified from plasmid PB-Gal4 (O’Brochta et al. 2012) using primers AscI-GAL4fw 
(5’-ATA GGC GCG CCA GCG CAG CTG AAC AAG CT-3’) and  GAL4Rv-BamHI 
(5’-ATA GGC GCG CCG TAA TAC GAC TCA CTA TAG GGC-3’) and inserted into 





cloning vectors were digested with AscI and BamHI (New England Biolabs (NEB) 
Ipswich, Mass.) and ligated with T4 DNA ligase (New England Biolabs (NEB) 
Ipswich, Mass.). Ligated product was transformed into E. coli DH10B (Gibco-BRL).   
Colonies were screened for insertion. Positive colonies were cultured and 
plasmid DNA extracted. The LRIM::Gal4 region was amplified from the plasmid 
using primers attB5-LRIMPromoter835 (5’- GGG GAC AAC TTT GTA TAC AAA 
AGT TGG GGC GAGGATGACCCACTAGAG-3’) and attB4-SV40Rv (5’-
GGGGACAACTTTGTATAGAAAAGTTGGGTGGGTTAAGATACATTGATGAG
TTTGGAC-3’that contained with gateway attachment sites. All the modules were 
brought together during site specific recombination. 
 
LRIM1-silencer  
 This is a piggyBac vector with 1.7 kilobases of 5’ terminal and 675 bases of 3’ 
terminal sequences of piggBac containing an inverted repeat of LRIM1 Gal4 under the 
regulatory control of the UAS enhancer in addition to a marker gene encoding  nuclear 
localized enhanced green fluorescent protein (nls EGFP) under the regulatory control 
of the 3xP3 promoter (Berghammer et al. 1999).  This vector was constructed using 
Gateway recombination cloning technology (Invitrogen, Grand Island, NY), in which 
4 recombination modules were simultaneously recombined into a destination plasmid. 
The first module consisted of the piggyBac left terminal and a nuclear localized EGFP 
(Addgene, Cambridge MA, USA) marker gene under the regulatory control of the 3xP3 
promoter (Berghammer et al. 1999). The second module contained a 202 base pair 





regulatory control of the UAS enhancer. The third module contained the inverted repeat 
of the 200 base pair LRIM1 region of the second module juxtaposed to SV40. The 
fourth module contained the piggyBac right terminal. Recombination between modules 
two and three joined the LRIM1 regions such that transcription resulted in generation 
of a short hairpin RNA.  
To create module one a 300 base pair (bp) region of 3xP3 (Berghammer et al. 
1999) was amplified using primers NotI-Fse 3xP3fw (5’-GCG GCCGCGGCCGGC 
CGTTCCCACAATGGTTAATTCG-3’) and PacI-AscI 3xP3rv (5’-GGCGCGCCT 
TAATTAAGGTACCGTCGACTCTAGC from plasmid attL5-3xP3-EGFP-SV40-
attL4. The resulting fragment with NotI/FseI and PacI/AscI restriction sites was 
inserted into a pCR4 Blunt-TOPO vector (Thermo Fisher Scientific Rockville MD, 
USA) to create plasmid 3xP3-pCR4. A 1.7 kilobase (kb) region of piggyBac left end 
from an in-house piggyBac vector was amplified using primers NotI-PBLeft fw (5’-
GCGGCCGCTACATACCTCGCTCTGC-3’) and FseI-PBLeftrv. The resulting 
amplified fragment with NotI and FseI restriction sites was inserted into a pCR4 Blunt-
TOPO vector (Thermo Fisher Scientific Rockville MD, USA) to create plasmid 
piggBacL-pCR4. A 1.1 kb region of nuclear localized eGFP (nls eGFP) from an in-
house plasmid pUAS-Stringer GFP was amplified using primers PacI-nlseGFPfw (5’-
TTAATTAAGATCCACCGGTCGCCAC-3’) and AscI-SV40rv (GGCG- 
CGCCTTAAGATACATTGATGAGTTTGGACAAACC-3’). The resulting PCR 
product with PacI and AscI restriction sites was inserted into a pCR4 Blunt-TOPO 
vector (Thermo Fisher Scientific Rockville MD, USA) to generate the nlseGFP-pCR4 





the piggyBacL-pCR4 and 3xP3-pCR4 plasmids. The 1.7 kb piggyBac left fragment that 
was generated, was collected and then ligated into a linearized 3xP3-pCR4 blunt 
plasmid using T4 DNA ligase (NEB) to generate a piggBacL-3xP3-pCR4 plasmid. 
Restriction digest using PacI (NEB) AscI (NEB) was performed on both the nlseGFP-
pCR4 and piggyBacL-3xP3-pCR4 plasmids. The 1.1 kb nlseGFP fragment that was 
generated, was collected and then ligated into a linearized piggyBacL-3xP3 pCR4 
plasmid using T4 DNA ligase (NEB). The 3.0 kb piggyBacL-3xP3-nlseGFP cassette 
was amplified using primers attB1-PBleftfw (5’-GGGGACAAGTTTGTACAA AAA 
AGC AGG CTG GTA CAT ACC TCG CTC TGC-3’) and attB5r-SV40 RV (5’- GGG 
GAC AAC TTTTGT ATA CAA AGTTGT TTAAGATACATTGATGAG TTT 
GGAC-3’) The amplified fragment with gateway tails was used for a BP reaction with 
a pDONOR to generate module 1. 
Plasmid pSLfa1180 i-CARB-SV40 (Kim, Koo, Richman, Seeley, Vizioli, et al. 
2004) was digested with SacI (NEB) and ApaI (NEB) to remove a 1.4 kb region that 
contained a NotI restriction enzyme site. The overhang ends of the 3.0 kb backbone 
were blunted using T4 DNA polymerase (NEB) and then re-circularized using T4 DNA 
ligase (NEB) to form plasmid pSLfa1180 delta. A 202 bp region of A. stephensi LRIM1 
was amplified using primers NheI-NotI-LRIM1fw (5’-GCAGCTAGCGCG GCCGC 
CGACTGTATC TGGCCAACAATAA-3’) and Xba-LRIM1 RV (5’- CAG TCT AGA 
GCG GCC GCC TAC GTT CCG CTG GTT CTT-3’) to introduce NheI, NotI and XbaI 
restriction sites. The amplified fragment was inserted into a pCR4 pCR4 Blunt-TOPO 
vector (Thermo Fisher Scientific Rockville MD, USA).  Plasmid pSL1180 delta and 





200 bp fragment from the digest of NheI-NotI-LRIM1-XbaI pCR4 was inserted into 
the linearized pSL1180 delta backbone using T4 DNA ligase to make plasmid pSL1180 
delta-LRIM1.  
A 255 bp region of tdTomato, was amplified and inserted into a pCR4 TOPO 
Blunt vector. To amplify tdTomato and introduce NheI and NotI restriction sites, 
primers NheI-tdTfw (5’-GCAGCTAGCGCGGCCGCCGACTGTATCTGGC   
CA ACAATAA-3’) and NotI tdTrv (5’-ATAGCGGCCGCCTACTTGTAC-3’) were 
used. The amplified fragment was inserted into a pCR4 Blunt-TOPO vector (Thermo 
Fisher Scientific Rockville MD, USA). The NheI-tdTomato-NotI pCR4 plasmid and 
plasmid pSL1180 delta-LRIM1 were both digested with NheI (NEB) and NotI (NEB). 
The 255 bp fragment of tdTomato released from the NheI-tdTomato-NotI pCR4 
plasmid was inserted into a linearized pSL1180 delta-LRIM1 plasmid using T4 DNA 
ligase (NEB) to form plasmid pSL1180 delta-LRIM1-tdT.  
To make module two a 767 bp region of plasmid pSL1180 delta-LRIM1-tdT 
was amplified using primers attB4-intron-SV40- attB5fw (5’-GGGACAATTTGTAT                                                                                                                                                                                                                     
ACAAAAGTTGCCTAC CACATTTGTAGAGGTTTTACTTGC-3') and 
attB4_intron_SV40_attB5rv (5’-GGGACAACTTTGTATAGAAAAGTTGGGTGAG 
GTGAGCACCCAATCATCAG-3'). The amplified fragment with gateway tails was 
used for a BP reaction with a pDONOR (Gateway, Thermo Fisher Rockville MD, 
USA) to generate module two.  
To generate module three a 457 bp region of plasmid pSL1180 delta-LRIM1-
tdT was amplified using primers attB3r-LRIM-tdTomato-attB4rfw (5’- GGGGAC 





and attB3r-LRIM_tdTomato-attB4rrv (5’-GGGGACAACTTTTCTATACAAAGTT 
GGGGGCACGCTGATCTACAAGGTG-3’). The amplified fragment with gateway 
tails was used for a BP reaction with a pDONOR (Gateway, Thermo Fisher Rockville 
MD, USA). To generate module 4 a 2210 bp region of an in-house plasmid ECFP-643 
was amplified using primers attB3-UAS-PiggBacR-attB2fw (5’-GGGGA 
CAACTTTGTATAATAAAGTTGCCTATTCAGAGTTCTCTTCTTGTATTC-3’) 
and attB3-UAS-PiggBacR-attB2rv (5’- GGGGACCACTTT GTACAAGAAAGCT 
GGGTAGGTGATGACGGTGAAAACCTC-3’). The amplified fragment  
with gateway tails was used for a BP reaction with a pDONOR (Gateway, Thermo 
Fisher Rockville MD, USA). The four modules where then recombined in a LR 
recombination reaction (Gateway, Thermo Fisher Rockville MD, USA).  
 
Mosquito Transformation 
 Transgenic A. stephensi were created in the University of Maryland, College 
Park, Institute for Bioscience and Biotechnology Research’s Insect Transformation 
Facility. Preblastoderm embryos of A. stephensi Sda 500 were injected with vector-
containing plasmids and plasmids expressing piggyBac transposase (Handler and 
Harrell 1999). The concentration of vectors and transposase-expressing plasmids were 
each 50 ng/microliter in injection buffer (5mM KCl, 0.1mM NaPO4; pH 6.8). Insects 
that developed from injected embryos and survived to adulthood were pooled according 
to sex and mated to non-injected Sda 500 adults of the opposite sex. The progeny were 





were used to establish lines. The piggyBac insertion sites were determined using 
splinkerette-PCR (Devon et al. 1995; Potter and Luo 2010) after lines were established. 
 
Splinkerette-PCR 
 Genomic DNA was extracted from mosquito as described earlier and suspended 
in 25µL of deionized H2O. 5µL of extracted DNA was digested with BstYI for 2 hours 
at 60oC in a final reaction volume of 35 µL. Digestion was then heat inactivated at 80oC 
for 20 mins. 50µL of SPLINK-BOT and SPLINK-GATC-TOP oligonucleotides were 
annealed in a NEB Buffer 2 solution of final volume 1000µL by heating at 95oC for 3 
minutes then cooled to room temperature. Annealed Spinkerette oligonucleotides are 
then ligated to digested genomic DNA using T4 DNA Ligase 400U/µL (New England 
Biolabs (NEB) Ipswich, Mass.) for 2 hours at room temperature. Round one of 
Splinkerette PCR was carried out using Phusion High-Fidelity polymerase (New 
England Biolabs (NEB) Ipswich, Mass.) with SPLNK#1 and 3’SPLNK-PB#1 or 
5’SPLNK-PB#1 primers.  
The PCR reaction was assembled as followed: 
Component    Volume (µL) 
5x HF Buffer                 5.0µL 
10mM dNTPs    0.5µL 
10µM SPLNK#1 primer  0.5µL 
10µM 5’ or 3’ SPLINK#1 primer 0.5µL 
diH20     8.25µL 





Phusion Polymerase   0.25µL 
PCR conditions 
1 cycle  
Denaturation 75 sec 98oC 
2 cycles 
Denaturation  20 sec 98oC 
Anneal  15 sec 64oC 
30 cycles 
 Denaturation 20 sec 98oC 
 Anneal  15 sec 58oC or 64oC 
 Elongation 2 min 72oC 
1 cycle 
 Elongation 7 min 72oC 
For the second round of amplification 1µL of the first PCR reaction was carried out 
using the secondary Splinkerette primers SPLNK#2 and 3’SPLNK-PB#2 or 5’SPLNK-
PB#2 under the following conditions: 
1 cycle  
Denaturation 75 sec 98oC 
30 cycles 
 Denaturation 20 sec 98oC 
 Anneal  15 sec  59oC or 66oC 






 Elongation 7 min 72oC 
The PCR product obtained was purified by gel electrophoresis on a 1.25% agarose gel 
then extracted using Quiagen, QIAquick gel extraction kit and sequenced using 5’PB 
sequence primer or 3’PB-sequence primer at Macrogen Inc, Rockville MD. 
 
Crossing Lines with Gal4 transgene with UAS-silencer lines 
 For all experiments that required analysis of mosquitoes with both the Gal4 
transgene and UAS::LRIM1silencer transgene in their genome, Heterozygous 
individuals of the UAS::LRIM1silencer and MBL24 GAL4 line were mated to produce 
progeny with all four genotypes: wild type; MBL24-Gal4/+ ; UAS::LRIM1silener/+ 
and MBL24-Gal4/UAS::LRIM1silencer. MBL24-Gal4 /+ ; UA S::LRIM1silener/+  and 


























 To screen for transgenic mosquitoes by microscopic observation of larvae, 
pupae, and adults an Olympus MVX10 fluorescent dissecting microscope equipped 
with Chroma filters (Chroma Technology Corporation, Bellows Falls, VT) 49001 ET-
CFP (excitation, 436/20; emission, 480/40; dichroic, 455), 49002 ET-GFP (excitation, 
470/40; emission, 525/50; dichroic, 495), 49003 ET-EYFP (excitation, 500/20; 
emission, 535/30; dichroic, 515), 49005 ET-DsRed (excitation, 545/30; emission, 
620/60; dichroic, 570) was used.  
For tissue imaging a Zeiss Axiom Imager A1 fluorescent compound microscope 
equipped with Zeiss filter set 20 (excitation, 546/12; emission, 575–640; dichroic, 560) 



















Appendix 1. Primers used for quantitative real-time polymerase chain reaction 
 
Name Sequence 
AsLRIM1-F GAG GAA AAT GCT CGG ATG AA 
AsLRIM1-R CGA CGG CTG AAC CTT ACT GA 
AsAPL1-F CTA CAG AGC GAA ATA CAG CA 
AsAPL1-R CAG ATG TGC TAT CAC CTT GT 
AsTEP1-F TTG CTG TCG TTC GTG ATA 
AsTEP1-R AGC GTG ATG GTG TAG TCG 
AsCaspar-F TGA CAT CTT CAC CGA AAC GCC 
AsCaspar-R AAC TGG ATG CTG CCA ATC GTC T 
AsRel2-F GTT CCG CTT CCG CTA TCA GT 
AsRel2-R CGC AAC TCT ACC GTG GGG AA 
tdTomato RT fw GCG TGA TGA ACT TCG AGG 
tdTomato RT rv CCT TGT AGA TCA GCG TGC C 
GAL1-fw CCA AAG AAA AAC CGA AGT GC 
GAL1-Rv CCC TAG TCA GCG GAG ACC TT 
AsS7r TTC GTT GTG AAC CCA AAT AAA AAT C 















Appendix 2. Primers used to construct LRIM1-silencer vector 
 
Names sequence 











































Appendix 3. Primers used for Splinkerette PCR 
 
Names Sequence 
5'SPNLK-PB-SEQ CGA CTG AGA TGT CCT AAA TGC 
5'SPLNK-PB#1 ACC GCA TTG ACA AGC ACG 
5'SPLNK-PB#2 CTC CAA GCG GCG ACT GAG 
3'SPLNK-PB-SEQ ACG CAT GAT TAT CTT TAA C 
3'SPLNK-PB#1 GTT TGT TGA ATT TAT TAT TAG TAT GTA AG 
3'SPLNK-PB#2 CGA TAA AAC ACA TGC GTC 
SPLNK#1 CGA AGA GTA ACC GTT GCT AGG AGA GAC C 
SPLNK#2 GTG GCT GAA TGA GAC TGG TGT CGA C 
SPLNK-GATC-
TOP 
GAT CCC ACT AGT GTC GAC ACC AGT CTC TAA TTT 
TTT TTT TCA AAA AAA 
SPLNK-BOT CGA AGA GTA ACC GTT GCT AGG AGA GAC CGT 
GGC TGA ATG AGA CTG GTG TCG ACA CTA GTG G 
SPLNK-Blunt-
TOP 
CC ACT AGT GTC GAC ACC AGT CTC TAA TTT TTT 
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